{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import re\n",
    "import string\n",
    "import rake_nltk\n",
    "from rake_nltk import Rake\n",
    "import operator\n",
    "import os\n",
    "#os.chdir('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\txt_data_final')\n",
    "from operator import itemgetter\n",
    "import nltk\n",
    "from collections import Counter\n",
    "\n",
    "import string\n",
    "from nltk.tokenize import RegexpTokenizer\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.stem import PorterStemmer\n",
    "ps = PorterStemmer()\n",
    "import pandas as pd\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "os.chdir('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\all_data_text_with_industry\\\\Financial')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Appending all file of a particular sector"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "#appending sector file( for every sector-make one appended file like healthcare appended/ financial appended)\n",
    "for file in os.listdir('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\all_data_text_with_industry\\\\Financial'):\n",
    "    d1 = open('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\all_data_text_with_industry\\\\Financial\\\\%s'%file,'r')\n",
    "    d2= d1.read()\n",
    "    Sec_1 = open(\"C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\fin_combined.txt\",\"a\")\n",
    "    Sec_1.write(d2)\n",
    "    Sec_1.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "d1 = open('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\fin_combined.txt','r')\n",
    "d2= d1.read()\n",
    "t = d2.split(\".\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Data preprocssesing of a sector"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "#extracting para only with misleading words\n",
    "Mislead = [\"mislead\", \"false\", \"omit\"]\n",
    "t1 = [ x for x in t if (len([y for y in Mislead if y in x]) > 0)]\n",
    "\n",
    "#para with misleading words\n",
    "t2 = \" \".join(x for x in t1)\n",
    "#fin_para = t2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\acer1\\Anaconda2\\lib\\site-packages\\ipykernel_launcher.py:3: UnicodeWarning: Unicode equal comparison failed to convert both arguments to Unicode - interpreting them as being unequal\n",
      "  This is separate from the ipykernel package so we can avoid doing imports until\n"
     ]
    }
   ],
   "source": [
    "#preprocessig of data\n",
    "token = tokenizer = RegexpTokenizer(r'\\w+')\n",
    "tokens = tokenizer.tokenize(t2)\n",
    "filtered_words = [ps.stem(w.decode('utf8', 'ignore')) for w in tokens if not w in stopwords.words('english')]\n",
    "ls = \" \".join(filtered_words)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "#removing unwanted numbers and common law words\n",
    "\n",
    "common_law_words = [\"defend\", \"cid\", \"compani\", \"class\", \"statement\", \n",
    "                    \"file\", \"plaintiff\", \"statement\", \"class\", \"file\", \"page\", \"action\", \"member\", \"case\",\n",
    "                   \"state\", \"alleg\", \"press\", \"releas\", \"materi\", \"herein\", \"complaint\", \"the\", \"for\"\n",
    "                   ]\n",
    "\n",
    "#removing common judge words & unwanter numbers\n",
    "filtered_words_2 = [ w for w in filtered_words if len(w) > 2 and not w in common_law_words]\n",
    "ls2 = \" \".join(filtered_words_2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "f = open(\"C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\FinProcessed.txt\", \"w\")\n",
    "f.write(ls2.encode(\"ascii\", \"ignore\"))\n",
    "f.close()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Analysis of text using bigram/Trigram"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      
       " ((u'liabil',), 378),\n",
       " ((u'persh',), 377),\n",
       " ((u'right',), 377),\n",
       " ((u'therebi',), 377),\n",
       " ((u'adjust',), 375),\n",
       " ((u'access',), 375),\n",
       " ((u'consist',), 374),\n",
       " ((u'sever',), 374)]"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Unigrams_fin = nltk.ngrams(ls2.split(),1)\n",
    "counter_uni_fin = Counter(Unigrams_fin)\n",
    "counter_uni_fin.most_common(400)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[((u'fals', u'mislead'), 2053),\n",
       " ((u'exchang', u'act'), 1465),\n",
       " ((u'per', u'share'), 1440),\n",
       " ((u'common', u'stock'), 1418),\n",
       
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Bigram_fin = nltk.ngrams(ls2.split(),2)\n",
    "counter_bi_fin = Counter(Bigram_fin)\n",
    "counter_bi_fin.most_common(400)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[((u'feder', u'secur', u'law'), 752),\n",
       " ((u'section', u'exchang', u'act'), 742),\n",
       " ((u'violat', u'feder', u'secur'), 505),\n",
       " ((u'artifici', u'inflat', u'price'), 450),\n",
       " ((u'control', u'financi', u'report'), 434),\n",
      
       " ((u'use', u'form', u'notic'), 75)]"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Trigram_fin = nltk.ngrams(ls2.split(),3)\n",
    "counter_tri_fin = Counter(Trigram_fin)\n",
    "counter_tri_fin.most_common(300)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[((u'violat', u'feder', u'secur', u'law'), 470),\n",
       " ((u'intern', u'control', u'financi', u'report'), 430),\n",
       " ((u'violat', u'section', u'exchang', u'act'), 333),\n",
       " ((u'million', u'per', u'dilut', u'share'), 235),\n",
       " 
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Search engine- searching the sentences with relevant word in the corpus"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "# Making code where if we input any word/list of word - it wqill return the paragraphs cointain those \n",
    "# words .It will help in extracting the desired sentences to find the relevance of that word.\n",
    "def search_fin(str_1):\n",
    "    word = str_1.split(' ')\n",
    "    sentence = fin_para.split(\".\")\n",
    "    word_sentence = [ w.replace(\"\\n\", \"\") for w in sentence if len([r for r in word if r in w]) > len(word)-1 ]\n",
    "    return set(word_sentence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'\\t1 have reviewed this annual report on Form 10-K of Regions FinancialCorporation;2 Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements weremade, not misleading with respect to the period covered by this report:3 On May 7, 2008, Regions filed its false and misleading interim financial report for thefirst quarter of 2008 with the SEC',\n",
       " \"  As officers and controlling persons of a publicly held company, whose common stock was and is traded on the NYSE, and is governed by the provisions of the federal securities laws, the Individual Defendants each had a duty to promptly disseminate accurate and truthful information with respect to the Company's financial condition, performance, growth, operations, financial statements, business, markets, management, earnings and present and future business prospects, and to correct any previously issued statements that had become materially misleading or untrue, so that the market price of the Company's common stock would be based upon truthful and accurate information\",\n",
       " \"  As officers, directors and controlling persons of a publicly-held company whose  common stock is and was registered with the SEC pursuant to the Securities Act and Exchange   Act, and was traded on the NASDAQ and governed by the provisions of the federal securities   laws, the Individual Defendants each had a duty to disseminate accurate and truthful information  promptly with respect to the Company's financial condition and to correct any previously-issued   statements that had become materially misleading or untrue to allow the market price of the   Company's publicly-traded stock to reflect truthful and accurate information\",\n",
       " '  As senior executive officers and/or directors and as controlling persons of a publicly traded company whose ADSs were, and are, registered with the SEC pursuant to the Exchange Act, and were, and are, traded on The NASDAQ Stock Market (\"NASDAQ\") and governed by the federal securities laws, the Individual Defendants had a duty to promptly disseminate accurate and truthful information with respect to CNinsure\\'s financial condition and performance, growth, operations, financial statements, business, products, markets, management, earnings and present and future business prospects, and to correct any previously issued statements that had become materially misleading or untrue, so that the market price of CNinsure ADSs would be based upon -3- \\x0cCase 1:11-cv-07320-VM Document 1 Filed 10/17/11 Page 5 of 28  truthful and accurate information',\n",
       " '  Based on the Company\\xe2\\x80\\x99s press releases commencing February 27, 2017, the financial statements contained in the Offering, or incorporated by reference therein, were materially untrue',\n",
       " '  Each of the Exchange Act Defendants\\xe2\\x80\\x99 statements that are identified above and were made throughout 2010 and 2011 concerning Orrstown\\xe2\\x80\\x99s financial condition, underwriting standards, loan portfolio quality, and internal controls were materially untrue and misleading',\n",
       " '  In addition, the statements made therein as to the adequacy of the Company\\xe2\\x80\\x99s financial controls  were  materially untrue',\n",
       " '  In addition, the statements made therein as to the adequacy of the Company\\xe2\\x80\\x99s financial controls were materially untrue',\n",
       " '  Shortly thereafter, it would be revealed that the \\xe2\\x80\\x9ccorrections\\xe2\\x80\\x9d were more than \\xe2\\x80\\x9cimmaterial\\xe2\\x80\\x9d, but rather the Company\\xe2\\x80\\x99s financial statements for the period 2014 through 2016 were materially untrue',\n",
       " '  The  general  disclosure requirement  prohibits  \"mak[ing]  publica  non-GAAP  financial  measure  that,  taken  together  with  the  information  accompanying  thatmeasure,  contains  an  untrue  statement  of  a  material  fact  or  omits  to  state  a  material  factnecessary in  order  to  make  the  presentation  of  the  non-GAAP  financial  measure',\n",
       " '  whether the Registration Statement issued by Orrstown included statements/omissions that were materially untrue or misleading about Orrstown\\xe2\\x80\\x99s internal controls, underwriting standards, loan portfolio quality, and financial condition;  d',\n",
       " \" All Defendants are sued either as primary participants in the wrongful and illegal conductcharged herein or as controlling persons as alleged below These defendants employed devices, schemes and artifices to defraud, while inpossession of material adverse non-public information and engaged in acts, practices, and a courseof conduct as alleged herein in an effort to assure investors of Green\\xe2\\x80\\x99s value and performance andcontinued substantial growth, which included the making of, or the participation in the making of,untrue statements of material facts and/or omitting to state material facts necessary in order to makethe statements made about Green and its business operations and future prospects in light of thecircumstances under which they were made, not misleading, as set forth more particularly herein,and engaged in transactions, practices and a course of business which operated as a fraud and deceitupon the purchasers of the Company\\xe2\\x80\\x99s securities during the Class Period Each of the Individual Defendants' primary liability, and controlling person liability,arises from the following facts: (i) the Individual Defendants were high-level executives and/ordirectors at the Company during the Class Period and members of the Company's management teamor had control thereof; (ii) each of these defendants, by virtue of their responsibilities and activitiesas a senior officer and/or director of the Company, was privy to and participated in the creation,development and reporting of the Company's internal budgets, plans, projections and/or reports; (iii)each of these defendants enjoyed significant personal contact and familiarity with the otherdefendants and was advised of, and had access to, other members of the Company's managementteam, internal reports and other data and information about the Company's finances, operations, andCOMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS31Case 2:10-cv-00253 Document 1 Filed 11/18/10 Page 31 of 35 PageID #: 31\\x0csales at all relevant times; and (iv) each of these defendants was aware of the Company'sdissemination of information to the investing public which they knew and/or recklessly disregardedwas materially false and misleading The defendants had actual knowledge of the misrepresentations and/or omissions ofmaterial facts set forth herein, or acted with reckless disregard for the truth in that they failed toascertain and to disclose such facts, even though such facts were available to them\",\n",
       " \" Among thequestions of law and fact common to the Class are:(a)(b)(c)Whether the 1933 Act was violated by Defendants' acts as alleged herein;Whether the Offering Materials issued by Defendants to the investing publicomitted and/or misrepresented material facts; andThe extent of injuries sustained by the Class and the appropriate measure ofdamages Contrary to the representations in the Offering Documents, neither defendantsMorgan Stanley, MS&Co, MSMC, Morgan Stanley Capital, nor the third-party loan originators,employed standards aimed at determining whether borrowers' financial strength and cash flowswere sufficient to meet the loan payments, Nor did they evaluate the borrowers' ability to repaytheir loans, The actual underwriting practices were in direct contradiction to the conservativepractices represented in the Offering Documents, thereby rendering the Offering Documentsmaterially untrue or misleading\",\n",
       " ' As officers and directors of a publicly-held company whose common stock was, and is, registered with the SEC pursuant to the Exchange Act, and was traded on the New York Stock Exchange (\"NYSE\"), and governed by the provisions of the federal securities laws, Defendants each had a duty to disseminate promptly, accurate and truthful information with respect to the Company\\'s financial condition and performance, growth, operations, financial statements, business, markets, management, earnings and present and future business prospects, and to correct any previously-issued statements that had become materially misleading or untrue, so that the market price of the Company\\'s publicly-traded common stock would be based upon truthful and accurate information',\n",
       " \" As officers, directors and controlling persons of a publicly-held company whose common stock is and was registered with the SEC pursuant to the Exchange Act, and was traded on the NYSE as an ADR and governed by the provisions of the federal securities laws, the Individual Defendants each had a duty to disseminate accurate and truthful information promptly with respect to the Company's financial condition and to correct any previously-published statements that were or had become materially misleading or untrue to allow the market price of the Company's publicly-traded stock to reflect truthful and accurate information\",\n",
       " \" As senior executive officers and/or directors and as controlling persons of a publicly traded companywhose common stock was, and is, registered with the SEC pursuant to the Exchange Act, and is traded on the New York Stock Exchange and governed by the federal securities laws, the Individual Defendants had a duty to promptly disseminate accurate and truthful information with respect to AAMC' s financial condition and performance, growth, operations, financial statements, business, products, markets, management, earnings, and present and future business prospects, to correct any previously issued statements that had become materially misleading or untrue, so the market price of AAMC' s common stock would be based on truthful and accurate information\",\n",
       " ' Based  on  the  Company\\xe2\\x80\\x99s  press  releases  commencing  February  27,  2017,  the financial statements contained in the Offering, or incorporated by reference therein, were material untrue',\n",
       " \" Based on my knowledge, this report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect tothe period covered by this report;3 These statements made by defendants were each materially false and misleadingwhen made, and were known by defendants to be false or were recklessly disregarded as suchthereby, for the following reasons, among others:(a)It was not true that the Company's purported success was the result of thegrowth in popularity of its new products and services, when, in fact, throughout the Class Period,defendants had propped up the Company's results by engaging in illegal and improper conduct,such that the Company was in violation of federal banking rules and/or regulations;(b)Unbeknownst to investors, defendants had materially overstated theCompany's profitability by failing to properly account for the Company's results of operationsand by artificially inflating the Company's financial results -- in part, through the inclusion of theiAdvance revenues that had been earned improperly or illegally;(c)Throughout the Class Period, it was also not true that Meta Financialcontained adequate systems of internal operational or financial controls, such that the Company'sreported financial statements were true, accurate or reliable; and,(d)As a result of the aforementioned adverse conditions which defendantsfailed to disclose, throughout the Class Period, defendants lacked any reasonable basis to claimthat Meta Financial was operating according to plan, or that Meta Financial could achieveguidance sponsored and/or endorsed by defendants As a result of this adjusted tax assumption, on July 6, 2009, defendants filed threeamended filings with the SEC: a Form 10-K/A for the fiscal year 2008, the year endedSeptember 30, 2008; a 1Q:F09 Form 10-Q/A for the quarter ending December 31, 2008; and a24:F09 Form 10-0/A, for the quarter ended March 31, 2009\",\n",
       " \" Because of their positions of control and authority as sen 5 officers of the Company and their control of the contents of the Company's financial statements 6 SEC disclosures, Thompson, Cameron and Wolford were able to, and did, control the contents of 7 Offering Materials during their respective periods of employment, which contained materially untrue 8 misleading information and omitted material facts\",\n",
       " ' Defendants identified in paragraphs 23 through 29 are members of the Board who adopted the invalid Bylaw in order to reduce their risk of being held liable to Imperial Holdings or its shareholders for violations of law and breaches of fiduciary duties, caused Imperial Holdings to file the false and misleading Proxy with the SEC, and aided, abetted, assisted, fostered, and directly participated in the nefarious scheme to file knowingly falsified and misleading structured settlement petitions in state courts across the country, which, upon information and belief, forms at least part of the purpose behind the ongoing IRS investigation, and which will result in the Company paying tens of millions of dollars in excise taxes to the IRS, on top of the fines and other penalties forthcoming',\n",
       " ' Defendantscaused the Offering Documents to contain materially untrue or misleading statements andomissions of material fact concerning the Certificates, and the loans underlying them, inviolation of the 1933 Act In summary, defendants made the following materially untrue or misleadingstatements in the Offering Documents;\\xe2\\x80\\xa2\\xe2\\x80\\xa2\\xe2\\x80\\xa2\\xe2\\x80\\xa2\\xe2\\x80\\xa2The loans supporting the Certificates were originated using underwritingstandards that evaluated a prospective borrower\\'s financial strength andability to repay the loan;Property appraisers\\' compensation was not affected by whether or not aloan was approved; appraisals of the properties underlying the loans werebased on recent sales of comparable properties; and the appraisalsconformed to the Uniform Standards of Professional Appraisal Practice(\"USPAP\"), Fannie Mae or Freddie Mac standards;At origination, the mortgage loans materially complied with all applicablefederal, state and local statutes and regulations;The loans underlying the Certificates had certain, specific, debt servicecoverage and loan-to-value (\"LTV\") ratios; andThe Certificates had \"investment grade\" credit ratings 4',\n",
       " \" I have reviewed this annual report on Form 10-K of Prospect Capital Corporation; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules  13a-15(e)  and  15d-15(e))  and internal control over financial reporting (as defined in Exchange Act Rules 13a 15(f) (cid:9)have: registrant (cid:9)15d-15(f)) (cid:9)and (cid:9)for (cid:9)the (cid:9)and (cid:9)(a) (b) (c) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over the financial reporting; and 8 \\x0cCase 1:14-cv-03761-AJN Document 2 Filed 05/27/14 Page 10 of 34  5\",\n",
       " \" I have reviewed this quarterly report on Form 10-Q of Enterprise Financial   Services Corp;  Based on my knowledge, this report does not contain any untrue statement  of a material fact or omit to state a material fact necessary to make the   statements made, in light of the circumstances under which such   statements were made, not misleading with respect to the period covered   by this report;  Based on my knowledge, the financial statements, and other financial  information included in this report, fairly present in all material respects  the financial condition, results of operations and cash flows of the  registrant as of, and for, the periods present in this report;  The registrant's other certifying officer(s) and I are responsible for  establishing and maintaining disclosure controls and procedures (as  defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal  control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:  a) b) c) Designed such disclosure controls and procedures, or caused such   disclosure controls and procedures to be designed under our   supervision, to ensure that material information relating to the  registrant, including its consolidated subsidiaries, is made known  to us by others within those entities, particularly during the period   in which this report is being prepared;  Designed such internal control over financial reporting, or caused  such internal control over financial reporting to be designed under  our supervision, to provide reasonable assurance regarding the  reliability of financial reporting and the preparation of financial  statements for external purposes in accordance with generally   accepted accounting principles;  Evaluated the effectiveness of the registrant's disclosure controls   and procedures and presented in this report our conclusions about  the effectiveness of the disclosure controls and procedures, as of   CLASS ACTION COMPLAINT  5  \\x0cCase: 4:12-cv-00637 Doc\",\n",
       " ' In truth, however, the foregoing statements, were materially untrue or misleading when made or omitted to state material facts necessary to make the statements made not misleading because,  inter alia, senior management did not implement internal controls and processes that would have prevented the Bank from (a) extending risky commercial loans throughout 2009 and 2010, resulting in a 7% growth in their commercial loan portfolio and further concentrating the Company\\xe2\\x80\\x99s overall loan portfolio in commercial loans and (b) periodically stress testing all existing commercial loans to ensure that the Company\\xe2\\x80\\x99s financial reporting accurately reflected the amount of non-performing loans and loan loss reserves which would have indicated to investors the riskiness of the Bank\\xe2\\x80\\x99s loan portfolio and potential for net-charge-offs',\n",
       " ' Inaddition to making substantially similar statements concerning the Company operations,including expenses, costs and ratios, as had been published previously, the 3Q:F09 Form 10-0also contained representations which attested to the purported effectiveness and sufficiency ofthe Company\\'s controls and procedures, as follows:DISCLOSURE CONTROLS AND PROCEDURESThe Company\\'s management, with the participation of the Company\\'s ChiefExecutive Officer and Chief Financial Officer, has evaluated the effectiveness ofthe Company\\'s \"disclosure controls and procedures\", as such term is defined inRules 13a \\xe2\\x80\\x94 15(e) and 15d \\xe2\\x80\\x94 15(e) of the Securities Exchange Act of 1934(Exchange Act) as of the end of the period covered by the report Based on my knowledge, this report does not contain any untrue statementof a material fact or omit to state a material fact necessary to make the statementsmade, in light of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report;Based on my knowledge, the financial statements, and other financial3 The statements made by defendants and contained in the Company\\'s August 10,2009 release and in the Company\\'s 3Q:F09 Form 10-0 were materially false and misleadingwhen made, and were know by defendants to be false at that time or were recklessly disregardedas such thereby for the reasons stated herein in 1f32,  supra By: /s/ David W',\n",
       " ' Notwithstanding his knowledge of the true facts regarding the related party nature of the Loan Transaction and Retention Payments, as well as the massive overvaluation of the Loans on the Company\\xe2\\x80\\x99s balance sheet, Reykdal certified financial statements that contained no related party transaction disclosures whatsoever, stating:  \\xe2\\x80\\x9cBased on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim  4 \\x0cCase 1:13-cv-03385-VM   Document 1   Filed 05/20/13   Page 5 of 19filings',\n",
       " ' Questions of law and fact common to the members of the Class whichpredominate over questions which may affect individual Class members include:(a)(b)(c)whether the 1934 Act was violated by defendants;whether defendants omitted and/or misrepresented material facts;whether defendants\\xe2\\x80\\x99 statements omitted material facts necessary to make thestatements made, in light of the circumstances under which they were made, not misleading;(d)whether defendants knew or deliberately disregarded that their statementswere false and misleading;(e)whether the price of Northern Trust common stock was artificially inflated;and- 6 -\\x0cCase 1:10-cv-05339 Document 1 Filed 08/24/10 Page 7 of 56(f)\\tthe extent of damage sustained by Class members and the appropriate measureof damages I have reviewed this report on Form 10-Q for the quarterly period endingSeptember 30, 2007 of Northern Trust Corporation;Based on my knowledge, this report does not contain any untrue statement ofa material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respects thefinancial condition, results of operations and cash flows of the registrant asof, and for, the periods presented in this report;The registrant\\xe2\\x80\\x99s other certifying officer(s) and I are responsible forestablishing and maintaining disclosure controls and procedures (as definedin Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control overfinancial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:- 13 -\\x0cCase 1:10-cv-05339 Document 1 Filed 08/24/10 Page 14 of 56(a)(b)(c)(d)Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to theregistrant, including its consolidated subsidiaries, is made known tous by others within those entities, particularly during the period inwhich this report is being prepared;Designed such internal control over financial reporting, or causedsuch internal control over financial reporting to be designed under oursupervision, to provide reasonable assurance regarding the reliabilityof financial reporting and the preparation of financial statements forexternal purposes in accordance with generally accepted accountingprinciples;Evaluated the effectiveness of the registrant\\xe2\\x80\\x99s disclosure controls andprocedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the endof the period covered by this report based on such evaluation; andDisclosed in this report any change in the registrant\\xe2\\x80\\x99s internal controlover financial reporting that occurred during the registrant\\xe2\\x80\\x99s mostrecent fiscal quarter (the registrant\\xe2\\x80\\x99s fourth fiscal quarter in the caseof an annual report) that has materially affected, or is reasonablylikely to materially affect, the registrant\\xe2\\x80\\x99s internal control overfinancial reporting; and5',\n",
       " ' The Individual Defendants, as executive officers and/or directors and as controlling persons of Nationstar, a publicly traded company whose common stock was governed by the federal securities laws and was registered with the NYSE, had a duty to promptly disseminate accurate and truthful information with respect to Nationstar\\xe2\\x80\\x99s financial condition and performance, growth, operations, financial statements, business, products, markets, management, earnings and present and future business prospects, and to correct any previously issued statements that had become materially misleading or untrue, so that the market price of Nationstar common stock would be based upon truthful and accurate information',\n",
       " \" The May 2009 and June 2010 Offering Materials contained untrue statements and omissions of material fact concerning,  inter alia, the Company's FX trading scheme, financial results and future business prospects\",\n",
       " ' TheIndividual Defendants are liable for the false statements pleaded herein, as those statements wereeach \\xe2\\x80\\x9cgroup-published\\xe2\\x80\\x9d information, and were the result of the collective actions of theIndividual Defendants In addition,the Q3 2016 Form 10-Q contained certifications signed byDefendants Bertolini and Guertin pursuant to \\xc2\\xa7302 of the Sarbanes-Oxley Act of 2002 (\\xe2\\x80\\x9cSOX\\xe2\\x80\\x9d),along with certifications signed solely by Defendant Bertolini as CEO, pursuant to \\xc2\\xa7906 of SOX,attesting that the financial information contained in the filing was true, did not omit materialfacts, and that the Company\\xe2\\x80\\x99s internal and disclosure controls were effective For instance, Defendants Bertolini and Guertin certified in the Q3 2016 Form 10-Q that:[T]his report does not contain any untrue statement of a material fact or omit tostate a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading withrespect to the period covered by this report The statements referenced in \\xc2\\xb6\\xc2\\xb629-37 were materially false and/or misleadingbecause they misrepresented and failed to disclose material adverse facts pertaining to the13\\x0cCase 3:17-cv-00113-SRU   Document 1   Filed 01/25/17   Page 16 of 35Company\\xe2\\x80\\x99s business and operations, which were known to Defendants or recklessly disregardedby them',\n",
       " ' These Defendants employed devices, schemes and artifices todefraud, while in possession of material adverse non-public information and engaged in acts,practices, and a course of conduct as alleged herein in an effort to assure investors of Aetna\\xe2\\x80\\x99svalue and performance and substantial growth, which included the making of, ortheparticipation in the making of, untrue statements of material facts, and omitting to state material26\\x0cCase 3:17-cv-00113-SRU   Document 1   Filed 01/25/17   Page 29 of 35facts necessary in order to make the statements made about Aetna and its business, operationsand future prospects, in light of the circumstances under which they were made, not misleading,as set forth more particularly herein, and engaged in transactions, practices and a course ofbusiness which operated as a fraud and deceit upon the purchasers of Aetna\\xe2\\x80\\x99s securities duringthe Class Period Each of the Individual Defendants\\xe2\\x80\\x99 primary liability, and controlling personliability, arises from the following facts: (i) each of the Individual Defendants was a high-levelexecutive and/or director at the Company during the Class Period; (ii) each of the IndividualDefendants, by virtue of his responsibilities and activities as a senior executive officer and/ordirector of the Company, was privy to and participated in the creation, development andreporting of the Company\\xe2\\x80\\x99s operational and financial projections and/or reports; (iii) theIndividual Defendants enjoyed significant personal contact and familiarity with each other, andwere advised of and had access to other members of the Company\\xe2\\x80\\x99s management team, internalreports, and other data and information aboutthe Company\\xe2\\x80\\x99s financial condition andperformance at all relevanttimes; and (iv) the Individual Defendants were aware of theCompany\\xe2\\x80\\x99s dissemination of information to the investing public which they knew or recklesslydisregarded was materially false and misleading Such Defendants\\xe2\\x80\\x99 material misrepresentations and/or omissions were done knowingly orrecklessly, and for the purpose and effect of concealing Aetna\\xe2\\x80\\x99s operating condition, businesspractices and future business prospects from the investing public and supporting the artificially27\\x0cCase 3:17-cv-00113-SRU   Document 1   Filed 01/25/17   Page 30 of 35inflated price of its common stock',\n",
       " ' These acts included the making of, or the participation in the making of, untrue statements of material facts and/or omitting to state material facts necessary in order to make the statements made about FXCM and its business operations and financial prospects, in light of the circumstances under which they were made, 17 \\x0cCase 1:15-cv-03599-KMW Document 1 Filed 05/08/15 Page 19 of 25 not misleading',\n",
       " \" With approximately  $25  trillion in assets under custody and administration, BNY Mellon is one of the largest custodial banks in the world and counts among its custodial clients some of the country's largest institutional investors, including financial institutions, states, cities, colleges, universities, foundations, non-profit religious organizations, and pension funds\",\n",
       " \" growth, operations, financial277R8CLASS ACTION COMPLAINT\\x0cCase 2:10-cv-06256-MMM -PJW Document 1 Filed 08/23/10 Page 9 of 54 Page ID #:101 statements, business, products, markets, management, earnings, and present and2 future business prospects, and to correct any previously-issued statements that had3become materially misleading or untrue, so that the market price of the Company's45 publicly-traded common stock would be based upon truthful and accurate6 information\",\n",
       " \"60$ 4,875$ 1,825$ 17,500$ 12,000$ 5,000$ 12,500$ 7,000$ 12,500$ 2,000$ 10,000$ 4,125June 1990\\tDecember 1999\\tMarch 1999\\tAugust 1999\\tDecember 2001\\tOctober 2003\\tMarch 2004\\tNovember 2004\\tMarch 2005\\tApril 2005\\tAugust 2005\\tNovember 2005\\tDecember 2005\\tJanuary 2006\\tJanuary 2006\\tApril 2006\\tMay 2006\\tOctober 2006\\tDecember 2006\\tMarch 2007\\tMarch 2007\\tAugust 2007\\tSeptember 2007\\tJune 2008\\tJanuary 2009\\tFebruary 2009\\tJuly 2009\\tNovember 2009\\tNovember 2009\\tDecember 2009\\tDecember 2009\\tDecember 2009\\tDecember 2009\\tFebruary 2010\\tMarch 2010\\tApril 2010\\tMay 2010\\tJune 2010\\tJuly 2010\\tAugust 2010\\tAugust 2010\\t18\\x0cCase 1:10-cv-00793-RJA Document 1 Filed 10/04/10 Page 19 of 3399 Upon information and belief, at least twenty (20) other individuals purchased falseand fictitious securities as a result of defendants' securities law violations and their losses exceedan additional $1,000,000 From approximately  1989 through the present, Geidel directly or indirectly, singlyor in concert, by the use of the means and instrumentalities of interstate commerce, of the mails,or the facilities of the national securities exchange, in connection with the purchase or sales ofsecurities, knowingly or recklessly: (a) employed devices, schemes, and artifices to defraud; (b)made untrue statements of material fact and omitted to state material facts necessary in order tomake the statements made, in light of the circumstances under which they were made, notmisleading; and/or (c) engaged in acts, practices, and/or courses of business which operated as afraud and deceit upon investors, purchasers of securities, and other persons As described above, Geidel made representations of fact to plaintiffs and otherClass members which were false Geidel knew that such representations were false when he made them and/or hemade such representations recklessly without regard for whether they were true or false In truth, the growth and financial results reported by PrivateBancorp during theClass Period were materially false and misleading because the Company concealed frominvestors that PrivateBancorp was routinely sacrificing loan quality for quantity in order toachieve certain financial targets to trigger incentive awards for its key employees\",\n",
       " '; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Unless otherwise noted, all underlining has been added throughout, 11 \\x0cCase 1:11-cv-07866-VM Document 1 Filed 11/03/11 Page 15 of 31  Registrant as of, and for, the periods presented in this report; 4',\n",
       " \"; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d- 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and  15d-15(f))  for the registrant and have: (a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; -21- \\x0cCase 2:12-cv-05275-SDW-MCA Document 1 Filed 08/22/12 Page 23 of 50 PageID: 23  (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5\",\n",
       " '; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; The registrant\\xe2\\x80\\x99s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a',\n",
       " \";Based on my knowledge, this report does not contain any untruestatement  of  a  material  fact  or  omit  to  state  a  material  factnecessary  to  make  the  statements  made,  in  light  of  thecircumstances  under  which  such  statements  were  made,  notmisleading with respect to the period covered by this report;Based  on  my  knowledge,  the  financial  statements,  and  otherfinancial information included in this report, fairly present in allmaterial respects the financial condition, results of operations andcash flows of the registrant as of, and for, the periods presented inthis report;The registrant's other certifying officers and I are responsible forestablishing and maintaining disclosure controls and procedures(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) andinternal control over financial reporting (as defined in ExchangeAct Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed  such  disclosure  controls  and  procedures,  orCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 7 \\x0c12345678910111213141516171819202122232425262728caused  such  disclosure  controls  and  procedures  to  bedesigned  under  our  supervision,  to  ensure  that  materialinformation  relating  to  the  registrant,  including  itsconsolidated subsidiaries, is made known to us by otherswithin those entities, particularly during the period in whichthis report is being prepared;(b) Designed such internal control over financial reporting, orcaused such internal control over financial reporting to bedesigned  under  our  supervision,  to  provide  reasonableassurance regarding the reliability of financial reporting andthe preparation of financial statements for external purposesin  accordance  with  generally  accepted  accountingprinciples;(c)Evaluated the effectiveness of the registrant's disclosurecontrols and procedures and presented in this report ourconclusions  about  the  effectiveness  of  the  disclosurecontrols and procedures, as of the end of the period coveredby this report based on such evaluation; and(d) Disclosed  in  this  report  any  change  in  the  registrant'sinternal  control  over  financial  reporting  that  occurredduring  the  registrant's  fourth  fiscal  quarter  that  hasmaterially  affected,  or  is  reasonably  likely  to  materiallyaffect,  the  registrant's  internal  control  over  financialreporting; andThe  registrant's  other  certifying  officers  and  I  have  disclosed,based  on  our  most  recent  evaluation  of  internal  control  overfinancial  reporting,  to  the  registrant's  auditors  and  the  auditcommittee  of  the  registrant's  board  of  directors  (or  personsperforming the equivalent functions):(a)All significant deficiencies and material weaknesses in thedesign  or  operation  of  internal  control  over  financialreporting which are reasonably likely to adversely affect theCLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS 8             5 The statements contained in  \\xc2\\xb6\\xc2\\xb617-25, were materially false and/ormisleading when made because defendants failed to disclose or indicate the following:(1) that the Company had deficiencies in its underwriting, origination, and renewalprocesses and procedures; (2) that the Company was not adhering to its underwritingpolicies; (3) that the Company lacked adequate internal and financial controls; and (4)that, as a result of the above, the Company's statements were materially false andmisleading at all relevant times\"}"
      ]
     },
     "execution_count": 139,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "search_fin(\"untr fin sta\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{' \\n\\n9 \\n\\n10 \\n\\n11 \\n\\n12 \\n\\n13 \\n\\n14 \\n\\n15 \\n\\n16 \\n\\n17 \\n\\n18 \\n\\n191 \\n\\n20 \\n\\n21 \\n\\n22 \\n\\n23 \\n\\n24 \\n\\n25 \\n\\n26 \\n\\n27 \\n\\n28 \\n\\nSection 10(b) of the Exchange Act and Rule 1 Ob-5 promulgated thereunder states \\n\\nthat: \\n\\nIt shall be unlawful for any person, directly or indirectly, by \\nthe use of any means or instrumentality of interstate \\ncommerce, or of the mails or of any facility of any national \\nsecurities exchange, \\n\\n(a) To employ any device, scheme, or artifice to \\n\\ndefraud, \\n\\n(b) To make any untrue statement of a material fact or \\nto omit to state a material fact necessary in order \\nto make the statements made, in the light of the \\ncircumstances under which they were made, not \\nmisleading, or \\n\\n(c) To engage in any act, practice or course of \\nbusiness which operates or woufd operate as a \\nfraud or deceit upon any person, in connection \\nwith the purchase or sale of any security',\n",
       " ' \\n\\nDefendant, individually and in concert, directly and indirectly, by the use, means \\n\\nor instrumentalities of interstate commerce and/or of the mails, engaged and participated in a \\n\\ncontinuous course of conduct to conceal adverse material information about Raser\\xe2\\x80\\x99s financial \\n\\nwell-being, business relationships, and prospects, as specified herein',\n",
       " ' \\n\\nDefendants,  individually  and  in  concert,  directly  and  indirectly,  by  the  use,  means  or \\n\\ninstrumentalities of interstate commerce and/or of the mails, engaged and participated in a continuous \\n\\ncourse of conduct to conceal adverse material information about the business and future prospects of \\n\\nLendingClub as specified herein',\n",
       " ' \
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "search_fin(\"indirect use mean\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# TECHNOLOGY SECTOR"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\acer1\\Anaconda2\\lib\\site-packages\\ipykernel_launcher.py:25: UnicodeWarning: Unicode equal comparison failed to convert both arguments to Unicode - interpreting them as being unequal\n"
     ]
    }
   ],
   "source": [
    "'''\n",
    "os.chdir('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\all_data_text_with_industry\\\\Technology')\n",
    "for file in os.listdir('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\all_data_text_with_industry\\\\Technology'):\n",
    "    d1 = open('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\all_data_text_with_industry\\\\Technology\\\\%s'%file,'r')\n",
    "    d2= d1.read()\n",
    "    Sec_1 = open(\"C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\Technology.txt\",\"a\")\n",
    "    Sec_1.write(d2)\n",
    "    Sec_1.close()\n",
    "'''\n",
    "    \n",
    "d1 = open('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\Technology.txt','r')\n",
    "d2= d1.read()\n",
    "t = d2.split(\".\\n\")\n",
    "\n",
    "\n",
    "Mislead = [\"mislead\", \"false\", \"omit\"]\n",
    "t1 = [ x for x in t if (len([y for y in Mislead if y in x]) > 0)]\n",
    "\n",
    "#para with misleading words\n",
    "t2 = \" \".join(x for x in t1)\n",
    "Tech_para = t2\n",
    "\n",
    "token = tokenizer = RegexpTokenizer(r'\\w+')\n",
    "tokens = tokenizer.tokenize(t2)\n",
    "filtered_words = [ps.stem(w.decode('utf8', 'ignore')) for w in tokens if not w in stopwords.words('english')]\n",
    "ls = \" \".join(filtered_words)\n",
    "\n",
    "\n",
    "common_law_words = [\"defend\", \"cid\", \"compani\", \"class\", \"statement\", \n",
    "                    \"file\", \"plaintiff\", \"statement\", \"class\", \"file\", \"page\", \"action\", \"member\", \"case\",\n",
    "                   \"state\", \"alleg\", \"press\", \"releas\", \"materi\", \"herein\", \"complaint\", \"the\", \"for\"\n",
    "                   ]\n",
    "\n",
    "#removing common judge words & unwanter numbers\n",
    "filtered_words_2 = [ w for w in filtered_words if len(w) > 2 and not w in common_law_words]\n",
    "ls2 = \" \".join(filtered_words_2)\n",
    "\n",
    "\n",
    "f = open(\"C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\TechProcessed.txt\", \"w\")\n",
    "f.write(ls2.encode(\"ascii\", \"ignore\"))\n",
    "f.close()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "Unigrams_tech = nltk.ngrams(ls2.split(),1)\n",
    "Bigram_tech = nltk.ngrams(ls2.split(),2)\n",
    "Trigram_tech = nltk.ngrams(ls2.split(),3)\n",
    "Fourgram_tech = nltk.ngrams(ls2.split(),4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def search_tech(str_1):\n",
    "    word = str_1.split(' ')\n",
    "    sentence = Tech_para.split(\".\")\n",
    "    word_sentence = [ w.replace(\"\\n\", \"\") for w in sentence if len([r for r in word if r in w]) > len(word)-1 ]\n",
    "    return set(word_sentence)"
   ]
  },
  {

       " ((u'n
       " ((u'contain', u'fulli', u'set'), 208),\n",
       " ((u'fraud', u'deceit', u'upon'), 208),\n",
       " ((u'use', u'mean', u'instrument'), 207),\n",
       " ((u'result', u'wrong', u'conduct'), 205),\n",
       " ((u'devic', u'scheme', u'artific'), 205),\n",
       " ((u'employ', u'devic', u'scheme'), 204),\n",
       " ((u'scheme', u'artific', u'defraud'), 203),\n",
       " ((u'issuanc', u'caus', u'correct'), 203),\n",
       " ((u'fail', u'disclos', u'fact'), 203),\n",
       " ((u'indirectli', u'use', u'mean'), 202),\n",
       " ((u'prevent', u'issuanc', u'caus'), 201),\n",
       " ((u'directli', u'indirectli', u'use'), 201),\n",
       " ((u'everi', u'contain', u'fulli'), 200),\n",
       " ((u'announc', u'financi', u'result'), 200),\n",
       " ((u'practic', u'cours', u'busi'), 200),\n",
       " ((u'proxi', u'fail', u'disclos'), 200),\n",
       " ((u'superior', u'avail', u'method'), 200),\n",
       " ((u'thi', u'court', u'jurisdict'), 200),\n",
       " ((u'fiscal', u'year', u'end'), 197),\n",
       " ((u'busi', u'oper', u'prospect'), 197),\n",
       " ((u'fairli', u'adequ', u'protect'), 197),\n",
       " ((u'act', u'1934', u'exchang'), 196),\n",
       " ((u'chang', u'intern', u'control'), 195),\n",
       " ((u'1934', u'exchang', u'act'), 193),\n",
       " ((u'within', u'mean', u'section'), 193),\n",
       " ((u'mislead', u'prior', u'shortli'), 192),\n",
       " ((u'effici', u'adjud', u'controversi'), 192),\n",
       " ((u'avail', u'method', u'fair'), 191),\n",
       " ((u'claim', u'typic', u'claim'), 190),\n",
       " ((u'all', u'other', u'similarli'), 189),\n",
       " ((u'price', u'per', u'share'), 189),\n",
       " ((u'method', u'fair', u'effici'), 189),\n",
       " ((u'relief', u'court', u'may'), 189),\n",
       " ((u'first', u'quarter', u'fiscal'), 189),\n",
       " ((u'fair', u'effici', u'adjud'), 188),\n",
       " ((u'court', u'may', u'deem'), 188),\n",
       " ((u'share', u'common', u'stock'), 188),\n",
       " ((u'pertin', u'part', u'follow'), 188),\n",
       " ((u'compar', u'net', u'incom'), 187),\n",
       " ((u'conduct', u'suffer', u'damag'), 184),\n",
       " ((u'net', u'loss', u'million'), 184),\n",
       " ((u'wrong', u'conduct', u'suffer'), 183),\n",
       " ((u'exchang', u'act', u'78j'), 183),\n",
       " ((u'issu', u'fals', u'mislead'), 183),\n",
       " ((u'set', u'forth', u'individu'), 182),\n",
       " ((u'juri', u'trial', u'demand'), 182),\n",
       " ((u'suffer', u'damag', u'connect'), 182),\n",
       " ((u'reckless', u'disregard', u'truth'), 182),\n",
       " ((u'claim', u'assert', u'aris'), 181),\n",
       " ((u'may', u'deem', u'proper'), 180),\n",
       " ((u'prayer', u'relief', u'wherefor'), 180),\n",
       " ((u'million', u'per', u'share'), 176),\n",
       " ((u'section', u'secur', u'act'), 176),\n",
       " ((u'rule', u'14a', u'promulg'), 176),\n",
       " ((u'inflat', u'price', u'period'), 175),\n",
       " ((u'act', u'practic', u'cours'), 172),\n",
       " ((u'fail', u'disclos', u'advers'), 170),\n",
       " ((u'behalf', u'all', u'other'), 169),\n",
       " ((u'engag', u'act', u'practic'), 167),\n",
       " ((u'disclosur', u'control', u'procedur'), 167),\n",
       " ((u'princip', u'execut', u'offic'), 167),\n",
       " ((u'upon', u'person', u'knowledg'), 167),\n",
       " ((u'liabl', u'pursuant', u'section'), 166),\n",
       " ((u'civil', u'procedur', u'behalf'), 166),\n",
       " ((u'fact', u'busi', u'oper'), 166),\n",
       " ((u'serv', u'repres', u'parti'), 166),\n",
       " ((u'stock', u'artifici', u'inflat'), 165),\n",
       " ((u'proxim', u'result', u'wrong'), 165),\n",
       " ((u'common', u'stock', u'trade'), 165),\n",
       " ((u'second', u'quarter', u'fiscal'), 165),\n",
       " ((u'pursuant', u'exchang', u'act'), 164),\n",
       " ((u'financi', u'oper', u'result'), 162),\n",
       " ((u'third', u'quarter', u'fiscal'), 161),\n",
       " ((u'discount', u'cash', u'flow'), 160),\n",
       " ((u'mean', u'section', u'exchang'), 159),\n",
       " ((u'protect', u'interest', u'retain'), 158),\n",
       " ((u'14a', u'promulg', u'thereund'), 155),\n",
       " ((u'act', u'against', u'individu'), 155),\n",
       " ((u'unlev', u'free', u'cash'), 153),\n",
       " ((u'reason', u'cost', u'expens'), 153),\n",
       " ((u'financi', u'inform', u'contain'), 153),\n",
       " ((u'share', u'revenu', u'billion'), 153),\n",
       " ((u'violat', u'section', u'1934'), 152),\n",
       " ((u'non', u'gaap', u'oper'), 152),\n",
       " ((u'experienc', u'secur', u'litig'), 152),\n",
       " ((u'interest', u'retain', u'counsel'), 152),\n",
       " ((u'section', u'secur', u'exchang'), 151),\n",
       " ((u'issu', u'announc', u'financi'), 151),\n",
       " ((u'connect', u'propos', u'transact'), 151),\n",
       " ((u'trade', u'artifici', u'inflat'), 151),\n",
       " ((u'fals', u'mislead', u'omiss'), 150),\n",
       " ((u'disclos', u'chang', u'intern'), 148),\n",
       " ((u'wholli', u'own', u'subsidiari'), 148),\n",
       " ((u'presid', u'chief', u'execut'), 148),\n",
       " ((u'approv', u'propos', u'transact'), 147),\n",
       " ((u'promulg', u'thereund', u'sec'), 146),\n",
       " ((u'execut', u'offic', u'ceo'), 145),\n",
       " ((u'individu', u'behalf', u'all'), 145),\n",
       " ((u'contain', u'sign', u'certif'), 145),\n",
       " ((u'gaap', u'net', u'incom'), 144),\n",
       " ((u'exchang', u'act', u'against'), 144),\n",
       " ((u'upon', u'inform', u'belief'), 144),\n",
       " ((u'day', u'day', u'oper'), 143),\n",
       " ((u'report', u'net', u'incom'), 143),\n",
       " ((u'incom', u'million', u'per'), 143),\n",
       " ((u'invest', u'public', u'period'), 143),\n",
       " ((u'statutori', u'safe', u'harbor'), 143),\n",
       " ((u'made', u'untru', u'fact'), 142),\n",
       " ((u'common', u'question', u'law'), 142),\n",
       " ((u'quarter', u'fiscal', u'year'), 142),\n",
       " ((u'interst', u'commerc', u'includ'), 142),\n",
       " ((u'purchas', u'common', u'stock'), 142),\n",
       " ((u'common', u'stock', u'artifici'), 141),\n",
       " ((u'three', u'month', u'end'), 141),\n",
       " ((u'fee', u'expert', u'fee'), 141),\n",
       " ((u'entiti', u'control', u'interest'), 141),\n",
       " ((u'sign', u'certif', u'pursuant'), 141),\n",
       " ((u'repres', u'parti', u'behalf'), 141),\n",
       " ((u'and', u'venu', u'claim'), 140),\n",
       " ((u'mail', u'interst', u'telephon'), 140),\n",
       " ((u'while', u'exact', u'number'), 140),\n",
       " ((u'interst', u'telephon', u'commun'), 140),\n",
       " ((u'successor', u'assign', u'entiti'), 140),\n",
       " ((u'telephon', u'commun', u'facil'), 140),\n",
       " ((u'disclos', u'fact', u'necessari'), 140),\n",
       " ((u'heir', u'successor', u'assign'), 139),\n",
       " ((u'number', u'unknown', u'time'), 139),\n",
       " ((u'unit', u'secur', u'exchang'), 138),\n",
       " ((u'secur', u'law', u'violat'), 138),\n",
       " ((u'assign', u'entiti', u'control'), 138),\n",
       " ((u'accur', u'disclos', u'chang'), 138),\n",
       " ((u'count', u'violat', u'section'), 138),\n",
       " ((u'exact', u'number', u'unknown'), 138),\n",
       " ((u'fact', u'set', u'forth'), 137),\n",
       " ((u'repres', u'heir', u'successor'), 137),\n",
       " ((u'involv', u'day', u'day'), 137),\n",
       " ((u'facil', u'nation', u'secur'), 137),\n",
       " ((u'report', u'form', u'sec'), 137),\n",
       " ((u'fraud', u'market', u'doctrin'), 136),\n",
       " ((u'law', u'fact', u'exist'), 136),\n",
       " ((u'customarili', u'use', u'secur'), 135),\n",
       " ((u'use', u'form', u'notic'), 135),\n",
       " ((u'violat', u'secur', u'exchang'), 135),\n",
       " ((u'venu', u'claim', u'assert'), 135),\n",
       " ((u'act', u'78j', u'78t'), 134),\n",
       " ((u'proxi', u'fals', u'mislead'), 134),\n",
       " ((u'misrepresent', u'fail', u'disclos'), 134),\n",
       " ((u'individu', u'act', u'control'), 134),\n",
       " ((u'dissemin', u'invest', u'public'), 134),\n",
       " ((u'mail', u'use', u'form'), 134),\n",
       " ((u'legal', u'repres', u'heir'), 134),\n",
       " ((u'non', u'gaap', u'net'), 134),\n",
       " ((u'pendenc', u'mail', u'use'), 133),\n",
       " ((u'immedi', u'famili', u'legal'), 133),\n",
       " ((u'announc', u'financi', u'oper'), 133),\n",
       " ((u'commun', u'facil', u'nation'), 133),\n",
       " ((u'identifi', u'record', u'maintain'), 133),\n",
       " ((u'1934', u'act', u'rule'), 133),\n",
       " ((u'transfer', u'agent', u'may'), 133),\n",
       " ((u'may', u'identifi', u'record'), 133),\n",
       " ((u'fals', u'mislead', u'proxi'), 132),\n",
       " ((u'78j', u'78t', u'rule'), 132),\n",
       " ((u'per', u'share', u'close'), 132),\n",
       " ((u'agent', u'may', u'notifi'), 132),\n",
       " ((u'herebi', u'demand', u'trial'), 132),\n",
       " ((u'violat', u'section', u'secur'), 131),\n",
       " ((u'unknown', u'time', u'ascertain'), 131),\n",
       " ((u'similar', u'customarili', u'use'), 131),\n",
       " ((u'notic', u'similar', u'customarili'), 131),\n",
       " ((u'form', u'notic', u'similar'), 131),\n",
       " ((u'counsel', u'compet', u'experienc'), 131),\n",
       " ((u'violat', u'feder', u'law'), 131),\n",
       " ((u'retain', u'counsel', u'compet'), 131),\n",
       " ((u'individu', u'violat', u'section'), 131),\n",
       " ((u'exist', u'predomin', u'question'), 130),\n",
       " ((u'individu', u'litig', u'make'), 130),\n",
       " ((u'wrong', u'conduct', u'violat'), 130),\n",
       " ((u'conduct', u'violat', u'feder'), 130),\n",
       " ((u'cash', u'flow', u'analysi'), 130),\n",
       " ((u'damag', u'suffer', u'individu'), 130),\n",
       " ((u'rel', u'small', u'expens'), 129),\n",
       " ((u'compet', u'experienc', u'secur'), 129),\n",
       " ((u'individu', u'may', u'rel'), 129),\n",
       " ((u'fals', u'mislead', u'inform'), 129),\n",
       " ((u'may', u'rel', u'small'), 129),\n",
       " ((u'famili', u'legal', u'repres'), 129),\n",
       " ((u'suffer', u'individu', u'may'), 129),\n",
       " ((u'notifi', u'pendenc', u'mail'), 129),\n",
       " ((u'may', u'notifi', u'pendenc'), 129),\n",
       " ((u'small', u'expens', u'burden'), 129),\n",
       " ((u'fact', u'exist', u'predomin'), 129),\n",
       " ((u'fals', u'mislead', u'made'), 128),\n",
       " ((u'ascertain', u'appropri', u'discoveri'), 128),\n",
       " ((u'per', u'share', u'cash'), 128),\n",
       " ((u'control', u'directli', u'indirectli'), 128),\n",
       " ((u'control', u'influenc', u'control'), 128),\n",
       " ((u'jurisdict', u'subject', u'matter'), 128),\n",
       " ((u'court', u'jurisdict', u'subject'), 128),\n",
       " ((u'individu', u'among', u'question'), 128),\n",
       " ((u'necessari', u'make', u'made'), 128),\n",
       " ((u'sole', u'affect', u'individu'), 127),\n",
       " ((u'deceit', u'upon', u'purchas'), 127),\n",
       " ((u'done', u'there', u'difficulti'), 127),\n",
       " ((u'there', u'difficulti', u'manag'), 127),\n",
       " ((u'affect', u'individu', u'among'), 127),\n",
       " ((u'quarter', u'end', u'march'), 127),\n",
       " ((u'accur', u'truth', u'inform'), 127),\n",
       " ((u'appropri', u'discoveri', u'believ'), 127),\n",
       " ((u'among', u'question', u'law'), 127),\n",
       " ((u'question', u'sole', u'affect'), 127),\n",
       " ((u'predomin', u'question', u'sole'), 127),\n",
       " ((u'wrong', u'done', u'there'), 126),\n",
       " ((u'deceiv', u'invest', u'public'), 126),\n",
       " ((u'proper', u'measur', u'damag'), 126),\n",
       " ((u'influenc', u'control', u'influenc'), 126),\n",
       " ((u'influenc', u'control', u'directli'), 126),\n",
       " ((u'similarli', u'affect', u'wrong'), 126),\n",
       " ((u'venu', u'proper', u'district'), 125),\n",
       " ((u'presumpt', u'relianc', u'establish'), 125),\n",
       " ((u'litig', u'make', u'imposs'), 125),\n",
       " ((u'affect', u'wrong', u'conduct'), 125),\n",
       " ((u'adjud', u'controversi', u'sinc'), 125),\n",
       " ((u'truth', u'inform', u'respect'), 124),\n",
       " ((u'sustain', u'damag', u'proper'), 124),\n",
       " ((u'oper', u'incom', u'million'), 124),\n",
       " ((u'typic', u'claim', u'similarli'), 124),\n",
       " ((u'includ', u'content', u'dissemin'), 124),\n",
       " ((u'violat', u'exchang', u'act'), 123)]"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Trigram_tech = nltk.ngrams(ls2.split(),3)\n",
    "counter_tri_tech = Counter(Trigram_tech)\n",
    "counter_tri_tech.most_common(300)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[((u'violat', u'feder', u'secur', u'law'), 1206),\n",
       " ((u'violat', u'section', u'exchang', u'act'), 626),\n",
       " ((u'intern', u'control', u'financi', u'report'), 493),\n",
       " ((u'secur', u'exchang', u'act', u'1934'), 423),\n",
       " ((u'feder', u'rule', u'civil', u'procedur'), 353),\n",
       " ((u'rule', u'10b', u'promulg', u'thereund'), 342),\n",
       " ((u'fact', u'omit', u'fact', u'necessari'), 336),\n",
       " ((u'million', u'per', u'dilut', u'share'), 335),\n",
       " ((u'light', u'circumst', u'made', u'mislead'), 315),\n",
       " ((u'untru', u'fact', u'omit', u'fact'), 312),\n",
       " ((u'fact', u'necessari', u'order', u'make'), 288),\n",
       " ((u'pursuant', u'section', u'exchang', u'act'), 277),\n",
       " ((u'repeat', u'realleg', u'everi', u'contain'), 268),\n",
       " ((u'section', u'exchang', u'act', u'rule'), 265),\n",
       " ((u'secur', u'artifici', u'inflat', u'price'), 260),\n",
       " ((u'make', u'made', u'light', u'circumst'), 255),\n",
       " ((u'necessari', u'order', u'make', u'made'), 255),\n",
       " ((u'made', u'light', u'circumst', u'made'), 253),\n",
       " ((u'secur', u'exchang', u'commiss', u'sec'), 245),\n",
       " ((u'question', u'law', u'fact', u'common'), 236),\n",
       " ((u'exchang', u'act', u'rule', u'10b'), 229),\n",
       " ((u'fals', u'mislead', u'fail', u'disclos'), 228),\n",
       " ((u'busi', u'oper', u'fraud', u'deceit'), 225),\n",
       " ((u'cours', u'busi', u'oper', u'fraud'), 224),\n",
       " ((u'per', u'dilut', u'share', u'revenu'), 222),\n",
       " ((u'rule', u'feder', u'rule', u'civil'), 221),\n",
       " ((u'omit', u'fact', u'necessari', u'make'), 215),\n",
       " ((u'mean', u'instrument', u'interst', u'commerc'), 210),\n",
       " ((u'order', u'make', u'made', u'light'), 207),\n",
       " ((u'oper', u'fraud', u'deceit', u'upon'), 207),\n",
       " ((u'use', u'mean', u'instrument', u'interst'), 205),\n",
       " ((u'employ', u'devic', u'scheme', u'artific'), 204),\n",
       " ((u'devic', u'scheme', u'artific', u'defraud'), 203),\n",
       " ((u'indirectli', u'use', u'mean', u'instrument'), 202),\n",
       " ((u'contain', u'fulli', u'set', u'forth'), 202),\n",
       " ((u'directli', u'indirectli', u'use', u'mean'), 201),\n",
       " ((u'prevent', u'issuanc', u'caus', u'correct'), 200),\n",
       " ((u'everi', u'contain', u'fulli', u'set'), 200),\n",
       " ((u'practic', u'cours', u'busi', u'oper'), 198),\n",
       " ((u'fairli', u'adequ', u'protect', u'interest'), 197),\n",
       " ((u'exchang', u'act', u'1934', u'exchang'), 195),\n",
       " ((u'omit', u'fact', u'necessari', u'order'), 194),\n",
       " ((u'act', u'1934', u'exchang', u'act'), 193),\n",
       " ((u'superior', u'avail', u'method', u'fair'), 191),\n",
       " ((u'all', u'other', u'similarli', u'situat'), 189),\n",
       " ((u'chang', u'intern', u'control', u'financi'), 189),\n",
       " ((u'relief', u'court', u'may', u'deem'), 188),\n",
       " ((u'avail', u'method', u'fair', u'effici'), 188),\n",
       " ((u'realleg', u'everi', u'contain', u'fulli'), 187),\n",
       " ((u'method', u'fair', u'effici', u'adjud'), 187),\n",
       " ((u'fair', u'effici', u'adjud', u'controversi'), 183),\n",
       " ((u'wrong', u'conduct', u'suffer', u'damag'), 182),\n",
       " ((u'court', u'may', u'deem', u'proper'), 180),\n",
       " ((u'artifici', u'inflat', u'price', u'period'), 169),\n",
       " ((u'conduct', u'suffer', u'damag', u'connect'), 169),\n",
       " ((u'result', u'wrong', u'conduct', u'suffer'), 168),\n",
       " ((u'act', u'rule', u'10b', u'promulg'), 168),\n",
       " ((u'rule', u'civil', u'procedur', u'behalf'), 166),\n",
       " ((u'proxim', u'result', u'wrong', u'conduct'), 165),\n",
       " ((u'behalf', u'all', u'other', u'similarli'), 162),\n",
       " ((u'direct', u'proxim', u'result', u'wrong'), 162),\n",
       " ((u'engag', u'act', u'practic', u'cours'), 162),\n",
       " ((u'mean', u'section', u'exchang', u'act'), 158),\n",
       " ((u'within', u'mean', u'section', u'exchang'), 157),\n",
       " ((u'adequ', u'protect', u'interest', u'retain'), 154),\n",
       " ((u'rule', u'14a', u'promulg', u'thereund'), 154),\n",
       " ((u'unlev', u'free', u'cash', u'flow'), 153),\n",
       " ((u'protect', u'interest', u'retain', u'counsel'), 152),\n",
       " ((u'dilut', u'share', u'revenu', u'billion'), 151),\n",
       " ((u'violat', u'section', u'1934', u'act'), 150),\n",
       " ((u'section', u'secur', u'exchang', u'act'), 149),\n",
       " ((u'disclos', u'chang', u'intern', u'control'), 148),\n",
       " ((u'presid', u'chief', u'execut', u'offic'), 147),\n",
       " ((u'section', u'exchang', u'act', u'78aa'), 145),\n",
       " ((u'individu', u'behalf', u'all', u'other'), 145),\n",
       " ((u'net', u'incom', u'million', u'per'), 143),\n",
       " ((u'chief', u'execut', u'offic', u'ceo'), 143),\n",
       " ((u'common', u'question', u'law', u'fact'), 141),\n",
       " ((u'instrument', u'interst', u'commerc', u'includ'), 140),\n",
       " ((u'contain', u'sign', u'certif', u'pursuant'), 140),\n",
       " ((u'liabl', u'pursuant', u'section', u'exchang'), 140),\n",
       " ((u'interst', u'telephon', u'commun', u'facil'), 139),\n",
       " ((u'jurisdict', u'and', u'venu', u'claim'), 139),\n",
       " ((u'unit', u'secur', u'exchang', u'commiss'), 138),\n",
       " ((u'accur', u'disclos', u'chang', u'intern'), 138),\n",
       " ((u'common', u'stock', u'artifici', u'inflat'), 138),\n",
       " ((u'mail', u'interst', u'telephon', u'commun'), 138),\n",
       " ((u'successor', u'assign', u'entiti', u'control'), 138),\n",
       " ((u'assign', u'entiti', u'control', u'interest'), 138),\n",
       " ((u'heir', u'successor', u'assign', u'entiti'), 137),\n",
       " ((u'repres', u'heir', u'successor', u'assign'), 137),\n",
       " ((u'while', u'exact', u'number', u'unknown'), 136),\n",
       " ((u'exact', u'number', u'unknown', u'time'), 136),\n",
       " ((u'made', u'untru', u'fact', u'omit'), 135),\n",
       " ((u'and', u'venu', u'claim', u'assert'), 135),\n",
       " ((u'venu', u'claim', u'assert', u'aris'), 135),\n",
       " ((u'involv', u'day', u'day', u'oper'), 135),\n",
       " ((u'violat', u'secur', u'exchang', u'act'), 135),\n",
       " ((u'mail', u'use', u'form', u'notic'), 134),\n",
       " ((u'individu', u'act', u'control', u'person'), 134),\n",
       " ((u'serv', u'repres', u'parti', u'behalf'), 134),\n",
       " ((u'question', u'law', u'fact', u'exist'), 134),\n",
       " ((u'announc', u'financi', u'oper', u'result'), 133),\n",
       " ((u'may', u'identifi', u'record', u'maintain'), 132),\n",
       " ((u'legal', u'repres', u'heir', u'successor'), 132),\n",
       " ((u'commun', u'facil', u'nation', u'secur'), 132),\n",
       " ((u'feder', u'secur', u'law', u'violat'), 132),\n",
       " ((u'misrepresent', u'fail', u'disclos', u'fact'), 132),\n",
       " ((u'pendenc', u'mail', u'use', u'form'), 132),\n",
       " ((u'retain', u'counsel', u'compet', u'experienc'), 131),\n",
       " ((u'transfer', u'agent', u'may', u'notifi'), 131),\n",
       " ((u'notic', u'similar', u'customarili', u'use'), 131),\n",
       " ((u'form', u'notic', u'similar', u'customarili'), 130),\n",
       " ((u'herebi', u'demand', u'trial', u'juri'), 130),\n",
       " ((u'number', u'unknown', u'time', u'ascertain'), 130),\n",
       " ((u'discount', u'cash', u'flow', u'analysi'), 129),\n",
       " ((u'fact', u'exist', u'predomin', u'question'), 129),\n",
       " ((u'damag', u'suffer', u'individu', u'may'), 129),\n",
       " ((u'similar', u'customarili', u'use', u'secur'), 129),\n",
       " ((u'notifi', u'pendenc', u'mail', u'use'), 129),\n",
       " ((u'counsel', u'compet', u'experienc', u'secur'), 129),\n",
       " ((u'law', u'fact', u'exist', u'predomin'), 129),\n",
       " ((u'interest', u'retain', u'counsel', u'compet'), 129),\n",
       " ((u'famili', u'legal', u'repres', u'heir'), 129),\n",
       " ((u'agent', u'may', u'notifi', u'pendenc'), 129),\n",
       " ((u'individu', u'may', u'rel', u'small'), 129),\n",
       " ((u'rel', u'small', u'expens', u'burden'), 129),\n",
       " ((u'act', u'78j', u'78t', u'rule'), 129),\n",
       " ((u'use', u'form', u'notic', u'similar'), 129),\n",
       " ((u'telephon', u'commun', u'facil', u'nation'), 129),\n",
       " ((u'immedi', u'famili', u'legal', u'repres'), 128),\n",
       " ((u'may', u'rel', u'small', u'expens'), 128),\n",
       " ((u'court', u'jurisdict', u'subject', u'matter'), 128),\n",
       " ((u'suffer', u'individu', u'may', u'rel'), 128),\n",
       " ((u'predomin', u'question', u'sole', u'affect'), 127),\n",
       " ((u'individu', u'among', u'question', u'law'), 127),\n",
       " ((u'thi', u'court', u'jurisdict', u'subject'), 127),\n",
       " ((u'fraud', u'deceit', u'upon', u'purchas'), 127),\n",
       " ((u'sole', u'affect', u'individu', u'among'), 127),\n",
       " ((u'question', u'sole', u'affect', u'individu'), 127),\n",
       " ((u'compet', u'experienc', u'secur', u'litig'), 127),\n",
       " ((u'done', u'there', u'difficulti', u'manag'), 127),\n",
       " ((u'section', u'exchang', u'act', u'78j'), 127),\n",
       " ((u'among', u'question', u'law', u'fact'), 127),\n",
       " ((u'influenc', u'control', u'directli', u'indirectli'), 126),\n",
       " ((u'ascertain', u'appropri', u'discoveri', u'believ'), 126),\n",
       " ((u'wrong', u'conduct', u'violat', u'feder'), 126),\n",
       " ((u'wrong', u'done', u'there', u'difficulti'), 126),\n",
       " ((u'may', u'notifi', u'pendenc', u'mail'), 126),\n",
       " ((u'exist', u'predomin', u'question', u'sole'), 125),\n",
       " ((u'affect', u'individu', u'among', u'question'), 125),\n",
       " ((u'similarli', u'affect', u'wrong', u'conduct'), 125),\n",
       " ((u'individu', u'litig', u'make', u'imposs'), 125),\n",
       " ((u'affect', u'wrong', u'conduct', u'violat'), 124),\n",
       " ((u'claim', u'typic', u'claim', u'similarli'), 124),\n",
       " ((u'conduct', u'violat', u'feder', u'law'), 123),\n",
       " ((u'typic', u'claim', u'similarli', u'affect'), 123),\n",
       " ((u'small', u'expens', u'burden', u'individu'), 123),\n",
       " ((u'burden', u'individu', u'litig', u'make'), 123),\n",
       " ((u'sustain', u'damag', u'proper', u'measur'), 123),\n",
       " ((u'time', u'ascertain', u'appropri', u'discoveri'), 123),\n",
       " ((u'made', u'fals', u'mislead', u'fail'), 123),\n",
       " ((u'effici', u'adjud', u'controversi', u'sinc'), 123),\n",
       " ((u'expens', u'burden', u'individu', u'litig'), 123),\n",
       " ((u'influenc', u'control', u'influenc', u'control'), 122),\n",
       " ((u'law', u'fact', u'common', u'whether'), 122),\n",
       " ((u'control', u'influenc', u'control', u'directli'), 122),\n",
       " ((u'violat', u'feder', u'law', u'complain'), 122),\n",
       " ((u'damag', u'proper', u'measur', u'damag'), 122),\n",
       " ((u'adjud', u'controversi', u'sinc', u'joinder'), 121),\n",
       " ((u'decis', u'make', u'includ', u'content'), 121),\n",
       " ((u'exchang', u'act', u'78j', u'78t'), 121),\n",
       " ((u'claim', u'similarli', u'affect', u'wrong'), 121),\n",
       " ((u'fact', u'necessari', u'make', u'made'), 121),\n",
       " ((u'includ', u'content', u'dissemin', u'variou'), 121),\n",
       " ((u'issu', u'announc', u'financi', u'result'), 121),\n",
       " ((u'unknown', u'time', u'ascertain', u'appropri'), 121),\n",
       " ((u'make', u'includ', u'content', u'dissemin'), 120),\n",
       " ((u'section', u'exchang', u'act', u'against'), 120),\n",
       " ((u'controversi', u'sinc', u'joinder', u'impractic'), 120),\n",
       " ((u'accur', u'truth', u'inform', u'respect'), 120),\n",
       " ((u'sinc', u'joinder', u'impractic', u'furthermor'), 119),\n",
       " ((u'count', u'violat', u'section', u'exchang'), 119),\n",
       " ((u'power', u'influenc', u'control', u'influenc'), 119),\n",
       " ((u'furthermor', u'damag', u'suffer', u'individu'), 119),\n",
       " ((u'directli', u'indirectli', u'decis', u'make'), 119),\n",
       " ((u'pursuant', u'feder', u'rule', u'civil'), 119),\n",
       " ((u'control', u'directli', u'indirectli', u'decis'), 119),\n",
       " ((u'content', u'dissemin', u'variou', u'contend'), 119),\n",
       " ((u'provid', u'unlimit', u'access', u'copi'), 118),\n",
       " ((u'10b', u'promulg', u'thereund', u'sec'), 118),\n",
       " ((u'impractic', u'furthermor', u'damag', u'suffer'), 118),\n",
       " ((u'dissemin', u'fals', u'mislead', u'inform'), 118),\n",
       " ((u'exchang', u'act', u'against', u'individu'), 117),\n",
       " ((u'relev', u'time', u'immedi', u'famili'), 117),\n",
       " ((u'demand', u'trial', u'juri', u'date'), 117),\n",
       " ((u'interest', u'numer', u'joinder', u'impractic'), 116),\n",
       " ((u'abil', u'prevent', u'issuanc', u'caus'), 116),\n",
       " ((u'redress', u'wrong', u'done', u'there'), 116),\n",
       " ((u'entiti', u'control', u'interest', u'numer'), 116),\n",
       " ((u'control', u'interest', u'numer', u'joinder'), 116),\n",
       " ((u'feder', u'secur', u'law', u'case3'), 115),\n",
       " ((u'indirectli', u'decis', u'make', u'includ'), 115),\n",
       " ((u'trade', u'artifici', u'inflat', u'price'), 115),\n",
       " ((u'advers', u'non', u'public', u'inform'), 115),\n",
       " ((u'net', u'loss', u'million', u'per'), 114),\n",
       " ((u'issu', u'abil', u'prevent', u'issuanc'), 114),\n",
       " ((u'litig', u'make', u'imposs', u'individu'), 114),\n",
       " ((u'joinder', u'impractic', u'furthermor', u'damag'), 114),\n",
       " ((u'time', u'immedi', u'famili', u'legal'), 114),\n",
       " ((u'record', u'owner', u'may', u'identifi'), 113),\n",
       " ((u'owner', u'may', u'identifi', u'record'), 113),\n",
       " ((u'bring', u'pursuant', u'feder', u'rule'), 113),\n",
       " ((u'imposs', u'individu', u'redress', u'wrong'), 113),\n",
       " ((u'individu', u'redress', u'wrong', u'done'), 112),\n",
       " ((u'individu', u'liabl', u'pursuant', u'section'), 112),\n",
       " ((u'incom', u'million', u'per', u'dilut'), 112),\n",
       " ((u'act', u'practic', u'cours', u'busi'), 112),\n",
       " ((u'make', u'imposs', u'individu', u'redress'), 112),\n",
       " ((u'offic', u'director', u'relev', u'time'), 111),\n",
       " ((u'particular', u'transact', u'give', u'rise'), 111),\n",
       " ((u'support', u'exist', u'set', u'forth'), 110),\n",
       " ((u'variou', u'contend', u'fals', u'mislead'), 110),\n",
       " ((u'influenc', u'particular', u'transact', u'give'), 110),\n",
       " ((u'dissemin', u'variou', u'contend', u'fals'), 110),\n",
       " ((u'jurisdict', u'subject', u'matter', u'pursuant'), 109),\n",
       " ((u'artific', u'defraud', u'made', u'untru'), 109),\n",
       " ((u'shortli', u'issu', u'abil', u'prevent'), 109),\n",
       " ((u'scheme', u'artific', u'defraud', u'made'), 109),\n",
       " ((u'control', u'influenc', u'particular', u'transact'), 109),\n",
       " ((u'power', u'control', u'influenc', u'particular'), 109),\n",
       " ((u'reli', u'upon', u'integr', u'market'), 109),\n",
       " ((u'evidentiari', u'support', u'exist', u'set'), 109),\n",
       " ((u'civil', u'procedur', u'behalf', u'consist'), 109),\n",
       " ((u'damag', u'superior', u'avail', u'method'), 108),\n",
       " ((u'mislead', u'prior', u'shortli', u'issu'), 108),\n",
       " ((u'proper', u'measur', u'damag', u'superior'), 108),\n",
       " ((u'defraud', u'made', u'untru', u'fact'), 108),\n",
       " ((u'prior', u'shortli', u'issu', u'abil'), 108),\n",
       " ((u'measur', u'damag', u'superior', u'avail'), 107),\n",
       " ((u'forth', u'reason', u'opportun', u'discoveri'), 107),\n",
       " ((u'act', u'against', u'individu', u'repeat'), 107),\n",
       " ((u'exist', u'set', u'forth', u'reason'), 107),\n",
       " ((u'form', u'sec', u'announc', u'financi'), 107),\n",
       " ((u'set', u'forth', u'reason', u'opportun'), 107),\n",
       " ((u'director', u'relev', u'time', u'immedi'), 106),\n",
       " ((u'fals', u'mislead', u'relev', u'time'), 106),\n",
       " ((u'numer', u'joinder', u'impractic', u'throughout'), 106),\n",
       " ((u'precipit', u'declin', u'market', u'valu'), 106),\n",
       " ((u'joinder', u'impractic', u'throughout', u'period'), 105),\n",
       " ((u'stock', u'artifici', u'inflat', u'price'), 105),\n",
       " ((u'new', u'york', u'new', u'york'), 105),\n",
       " ((u'individu', u'repeat', u'realleg', u'everi'), 105),\n",
       " ((u'actual', u'knowledg', u'misrepresent', u'omiss'), 105),\n",
       " ((u'presum', u'power', u'control', u'influenc'), 105),\n",
       " ((u'act', u'reckless', u'disregard', u'truth'), 105),\n",
       " ((u'particip', u'awar', u'oper', u'intim'), 105),\n",
       " ((u'chief', u'financi', u'offic', u'cfo'), 105),\n",
       " ((u'prayer', u'relief', u'wherefor', u'pray'), 105),\n",
       " ((u'appropri', u'discoveri', u'believ', u'hundr'), 104),\n",
       " ((u'awar', u'oper', u'intim', u'knowledg'), 104),\n",
       " ((u'fulli', u'set', u'forth', u'individu'), 104),\n",
       " ((u'fulli', u'set', u'forth', u'dure'), 104),\n",
       " ((u'interst', u'commerc', u'includ', u'limit'), 104),\n",
       " ((u'use', u'secur', u'claim', u'typic'), 104),\n",
       " ((u'reckless', u'disregard', u'truth', u'fail'), 104),\n",
       " ((u'customarili', u'use', u'secur', u'claim'), 103),\n",
       " ((u'whether', u'made', u'invest', u'public'), 103),\n",
       " ((u'secur', u'claim', u'typic', u'claim'), 103),\n",
       " ((u'therefor', u'presum', u'power', u'control'), 103),\n",
       " ((u'day', u'day', u'oper', u'therefor'), 103),\n",
       " ((u'whether', u'feder', u'secur', u'law'), 103),\n",
       " ((u'specif', u'made', u'fals', u'mislead'), 102),\n",
       " ((u'misrepres', u'fact', u'busi', u'oper'), 102),\n",
       " ((u'suffer', u'signific', u'loss', u'damag'), 102),\n",
       " ((u'confidenti', u'proprietari', u'inform', u'concern'), 102),\n",
       " ((u'would', u'purchas', u'otherwis', u'acquir'), 101),\n",
       " ((u'non', u'gaap', u'net', u'incom'), 101),\n",
       " ((u'privi', u'confidenti', u'proprietari', u'inform'), 101),\n",
       " ((u'supervisori', u'involv', u'day', u'day'), 101),\n",
       " ((u'complain', u'fairli', u'adequ', u'protect'), 101),\n",
       " ((u'act', u'direct', u'proxim', u'result'), 101),\n",
       " ((u'secur', u'law', u'violat', u'act'), 101),\n",
       " ((u'against', u'individu', u'repeat', u'realleg'), 101),\n",
       " ((u'78j', u'78t', u'rule', u'10b'), 101),\n",
       " ((u'sec', u'announc', u'financi', u'oper'), 101),\n",
       " ((u'venu', u'proper', u'district', u'pursuant'), 100),\n",
       " ((u'wrong', u'act', u'omiss', u'precipit'), 100),\n",
       " ((u'non', u'gaap', u'oper', u'incom'), 100),\n",
       " ((u'direct', u'supervisori', u'involv', u'day'), 100),\n",
       " ((u'result', u'wrong', u'act', u'omiss'), 100),\n",
       " ((u'day', u'oper', u'therefor', u'presum'), 99),\n",
       " ((u'damag', u'therebi', u'dure', u'period'), 99),\n",
       " ((u'omiss', u'precipit', u'declin', u'market'), 99),\n",
       " ((u'act', u'omiss', u'precipit', u'declin'), 99),\n",
       " ((u'feder', u'law', u'complain', u'fairli'), 99),\n",
       " ((u'law', u'complain', u'fairli', u'adequ'), 99),\n",
       " ((u'virtu', u'posit', u'control', u'person'), 98),\n",
       " ((u'common', u'whether', u'feder', u'secur'), 98),\n",
       " ((u'fact', u'common', u'whether', u'feder'), 98),\n",
       " ((u'mislead', u'fail', u'disclos', u'advers'), 98),\n",
       " ((u'78t', u'rule', u'10b', u'promulg'), 98),\n",
       " ((u'facil', u'nation', u'secur', u'exchang'), 98),\n",
       " ((u'00227', u'lmb', u'jfa', u'document'), 97),\n",
       " ((u'lmb', u'jfa', u'document', u'pageid'), 97),\n",
       " ((u'exchang', u'act', u'sec', u'rule'), 97),\n",
       " ((u'non', u'gaap', u'financi', u'measur'), 96),\n",
       " ((u'award', u'reason', u'cost', u'expens'), 96),\n",
       " ((u'240', u'10b', u'thi', u'court'), 96),\n",
       " ((u'set', u'forth', u'dure', u'period'), 96),\n",
       " ((u'made', u'invest', u'public', u'period'), 96),\n",
       " ((u'oper', u'therefor', u'presum', u'power'), 95),\n",
       " ((u'declin', u'market', u'valu', u'secur'), 95),\n",
       " ((u'oper', u'intim', u'knowledg', u'fals'), 95),\n",
       " ((u'reason', u'cost', u'expens', u'incur'), 94),\n",
       " ((u'10b', u'thi', u'court', u'jurisdict'), 94),\n",
       " ((u'claim', u'assert', u'aris', u'pursuant'), 94),\n",
       " ((u'unit', u'mail', u'interst', u'telephon'), 94),\n",
       " ((u'individu', u'breach', u'fiduciari', u'duti'), 94),\n",
       " ((u'believ', u'hundr', u'thousand', u'propos'), 93),\n",
       " ((u'market', u'valu', u'secur', u'suffer'), 93),\n",
       " ((u'stoll', u'bern', u'lokt', u'shlachter'), 93),\n",
       " ((u'omiss', u'virtu', u'posit', u'control'), 93),\n",
       " ((u'oak', u'street', u'suit', u'500'), 93),\n",
       " ((u'209', u'oak', u'street', u'suit'), 93),\n",
       " ((u'discoveri', u'believ', u'hundr', u'thousand'), 93),\n",
       " ((u'act', u'omiss', u'virtu', u'posit'), 93),\n",
       " ((u'secur', u'suffer', u'signific', u'loss'), 93),\n",
       " ((u'deceiv', u'invest', u'public', u'includ'), 93),\n",
       " ((u'stoll', u'stoll', u'bern', u'lokt'), 93),\n",
       " ((u'valu', u'secur', u'suffer', u'signific'), 93),\n",
       " ((u'common', u'stock', u'period', u'suffer'), 93),\n",
       " ((u'cost', u'expens', u'incur', u'includ'), 92),\n",
       " ((u'princip', u'execut', u'offic', u'locat'), 92),\n",
       " ((u'section', u'exchang', u'act', u'virtu'), 92),\n",
       " ((u'damag', u'sustain', u'result', u'wrongdo'), 92),\n",
       " ((u'new', u'york', u'stock', u'exchang'), 91),\n",
       " ((u'section', u'1934', u'act', u'rule'), 91),\n",
       " ((u'against', u'all', u'repeat', u'realleg'), 91),\n",
       " ((u'damag', u'connect', u'respect', u'purchas'), 91),\n",
       " ((u'promulg', u'thereund', u'sec', u'240'), 91),\n",
       " ((u'suffer', u'damag', u'connect', u'respect'), 91),\n",
       " ((u'exclud', u'offic', u'director', u'relev'), 90),\n",
       " ((u'lokt', u'shlachter', u'209', u'oak'), 90),\n",
       " ((u'financi', u'oper', u'result', u'quarter'), 90),\n",
       " ((u'shlachter', u'209', u'oak', u'street'), 90),\n",
       " ((u'fail', u'disclos', u'fact', u'necessari'), 90),\n",
       " ((u'throughout', u'period', u'deceiv', u'invest'), 90),\n",
       " ((u'procedur', u'behalf', u'consist', u'purchas'), 90),\n",
       " ((u'conduct', u'particip', u'directli', u'indirectli'), 90),\n",
       " ((u'bern', u'lokt', u'shlachter', u'209'), 90),\n",
       " ((u'damag', u'favor', u'jointli', u'sever'), 90),\n",
       " ((u'act', u'whether', u'made', u'invest'), 89),\n",
       " ((u'becaus', u'posit', u'control', u'author'), 89),\n",
       " ((u'scheme', u'plan', u'cours', u'conduct'), 89),\n",
       " ((u'intend', u'throughout', u'period', u'deceiv'), 89),\n",
       " ((u'violat', u'act', u'whether', u'made'), 89),\n",
       " ((u'award', u'compensatori', u'damag', u'favor'), 89),\n",
       " ((u'unlaw', u'scheme', u'plan', u'cours'), 88),\n",
       " ((u'alter', u'total', u'mix', u'inform'), 88),\n",
       " ((u'includ', u'among', u'thing', u'review'), 88),\n",
       " ((u'compar', u'net', u'incom', u'million'), 88),\n",
       " ((u'period', u'deceiv', u'invest', u'public'), 88),\n",
       " ((u'fiscal', u'year', u'end', u'decemb'), 87),\n",
       " ((u'tel', u'503', u'227', u'1600'), 87),\n",
       " ((u'revenu', u'billion', u'compar', u'net'), 87),\n",
       " ((u'law', u'violat', u'act', u'whether'), 87),\n",
       " ((u'fax', u'503', u'227', u'6840'), 87),\n",
       " ((u'section', u'exchang', u'act', u'sec'), 87),\n",
       " ((u'1600', u'fax', u'503', u'227'), 87),\n",
       " ((u'billion', u'compar', u'net', u'incom'), 87),\n",
       " ((u'227', u'1600', u'fax', u'503'), 87),\n",
       " ((u'sarban', u'oxley', u'act', u'2002'), 87),\n",
       " ((u'further', u'unlaw', u'scheme', u'plan'), 87),\n",
       " ((u'favor', u'jointli', u'sever', u'damag'), 87),\n",
       " ((u'fail', u'disclos', u'advers', u'inform'), 87),\n",
       " ((u'503', u'227', u'1600', u'fax'), 87),\n",
       " ((u'wrongdo', u'amount', u'proven', u'trial'), 86),\n",
       " ((u'jointli', u'sever', u'damag', u'sustain'), 86),\n",
       " ((u'disclos', u'fact', u'necessari', u'order'), 86),\n",
       " ((u'suffer', u'damag', u'connect', u'purchas'), 86),\n",
       " ((u'individu', u'provid', u'unlimit', u'access'), 86),\n",
       " ((u'amount', u'proven', u'trial', u'includ'), 86),\n",
       " ((u'compensatori', u'damag', u'favor', u'jointli'), 86),\n",
       " ((u'upon', u'revel', u'correct', u'disclosur'), 85),\n",
       " ((u'includ', u'counsel', u'fee', u'expert'), 85),\n",
       " ((u'sever', u'damag', u'sustain', u'result'), 85),\n",
       " ((u'result', u'wrongdo', u'amount', u'proven'), 85),\n",
       " ((u'all', u'repeat', u'realleg', u'everi'), 85),\n",
       " ((u'trial', u'includ', u'interest', u'thereon'), 85),\n",
       " ((u'proven', u'trial', u'includ', u'interest'), 85),\n",
       " ((u'propos', u'record', u'owner', u'may'), 85),\n",
       " ((u'damag', u'upon', u'revel', u'correct'), 85),\n",
       " ((u'advers', u'inform', u'misrepres', u'truth'), 85),\n",
       " ((u'sustain', u'result', u'wrongdo', u'amount'), 85),\n",
       " ((u'transact', u'practic', u'cours', u'busi'), 85),\n",
       " ((u'counsel', u'fee', u'expert', u'fee'), 85),\n",
       " ((u'report', u'form', u'sec', u'announc'), 85),\n",
       " ((u'disclos', u'advers', u'inform', u'misrepres'), 85),\n",
       " ((u'issuanc', u'abil', u'opportun', u'prevent'), 84)]"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Fourgram_tech = nltk.ngrams(ls2.split(),4)\n",
    "counter_four_tech = Counter(Fourgram_tech)\n",
    "counter_four_tech.most_common(400)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "collapsed": true
   },
   "source": [
    "# Analysis for healthcare sector: code in same format as above"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Healthcare"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\acer1\\Anaconda2\\lib\\site-packages\\ipykernel_launcher.py:14: UnicodeWarning: Unicode equal comparison failed to convert both arguments to Unicode - interpreting them as being unequal\n",
      "  \n"
     ]
    }
   ],
   "source": [
    "d1 = open('C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\\\HC_combined.txt','r')\n",
    "d2= d1.read()\n",
    "t = d2.split(\".\\n\")\n",
    "\n",
    "Mislead = [\"mislead\", \"false\", \"omit\"]\n",
    "t1 = [ x for x in t if (len([y for y in Mislead if y in x]) > 0)]\n",
    "\n",
    "#para with misleading words\n",
    "t2 = \" \".join(x for x in t1)\n",
    "HC_para = t2\n",
    "\n",
    "token = tokenizer = RegexpTokenizer(r'\\w+')\n",
    "tokens = tokenizer.tokenize(t2)\n",
    "filtered_words = [ps.stem(w.decode('utf8', 'ignore')) for w in tokens if not w in stopwords.words('english')]\n",
    "ls = \" \".join(filtered_words)\n",
    "\n",
    "\n",
    "common_law_words = [\"defend\", \"cid\", \"compani\", \"class\", \"statement\", \n",
    "                    \"file\", \"plaintiff\", \"statement\", \"class\", \"file\", \"page\", \"action\", \"member\", \"case\",\n",
    "                   \"state\", \"alleg\", \"press\", \"releas\", \"materi\", \"herein\", \"complaint\", \"the\", \"for\"\n",
    "                   ]\n",
    "\n",
    "#removing common judge words & unwanter numbers\n",
    "filtered_words_2 = [ w for w in filtered_words if len(w) > 2 and not w in common_law_words]\n",
    "ls2 = \" \".join(filtered_words_2)\n",
    "\n",
    "\n",
    "f = open(\"C:\\\\Users\\\\acer1\\\\Desktop\\\\Starr mine\\HcProcessed.txt\", \"w\")\n",
    "f.write(ls2.encode(\"ascii\", \"ignore\"))\n",
    "f.close()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def search_Hc(str_1):\n",
    "    word = str_1.split(' ')\n",
    "    sentence = HC_para.split(\".\")\n",
    "    word_sentence = [ w.replace(\"\\n\", \"\") for w in sentence if len([r for r in word if r in w]) > len(word)-1 ]\n",
    "    return set(word_sentence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'\\tDefendants\\xe2\\x80\\x99 statements in paragraphs 36 to 52 above, were materially false and2 misleading because, contrary to the repeated and express trumpeting of Qnexa\\xe2\\x80\\x99s safety profile:3\\t(a)\\tthe studies conducted by Vivus and submitted to the FDA Panel could not4 support FDA Panel approval for Qnexa\\xe2\\x80\\x99s use to treat obesity as a chronic condition, and longer-5 term clinical studies would be needed to determine whether Qnexa was safe for its intended use6 to treat chronic obesity;7\\t(b)\\tthe trial results showed significant and worrisome adverse effects of the8 type that scuttled approval for other obesity drugs, including: increased risk of suicide,9 cardiovascular events, and birth defects;10\\t(c)\\tfour to seven times as many patients taking the highest dose of Qnexa,11 compared to patients taking lower doses or placebos, dropped out of the study because of adverse12 side effects such as anxiety, sleep disorders, or depression;13\\t(d)\\tQnexa would likely receive a \\xe2\\x80\\x9cPregnancy Category X\\xe2\\x80\\x9d label from the14 FDA due to birth defects (teratogenicity) risk, instead of the proposed \\xe2\\x80\\x9cPregnancy Category C\\xe2\\x80\\x9d15 label, thereby potentially eliminating a huge swath of potential Qnexa customers 16\\t53',\n",
       " \"\\tOn February 17, 2010, defendants were forced to publicly disclose that the FDA had7 issued a complete response letter regarding 512 such that it had denied approval of the Company's8 RLS drug, Horizant, with concerns about laboratory study results showing pancreatic cell tumors in9 rats as a result of the drug\",\n",
       " \"\\tSpecifically, throughout the Class Period, defendants violated the federal securities9 laws by disseminating false and misleading statements to the investing public and concealing10 negative information, making it impossible for shareholders to gain a meaningful or realisticI 1 understanding of the drug's progress toward FDA approval and market success 18\\t10\",\n",
       " '    If  approved  by  the  FDA,  we believe SER-109 could  be  a  first-in-field  drug,  which  will  require  manufacturing capabilities  that  are  distinct  from  other  biologic  drugs',\n",
       " '    If  approved, RexistaTM  may  be  the  only  abuse-deterrent  oxycodone  product  with properties that may provide early warning of drug abuse if the product is  manipulated  or  abused',\n",
       " '    Roche has already secured regulatory approval for the combination in some breast cancer sufferers, but oncologists could decide to stick to the single drug for the majority of patients after seeing the data',\n",
       " '    The  Company  sought  FDA  approval  to  label  the  drug  as  an \\xe2\\x80\\x9cabuse-deterrent formulation\\xe2\\x80\\x9d (\\xe2\\x80\\x9cADF\\xe2\\x80\\x9d) on the basis that crushing or grinding benzhydrocodone would not have any impact on its release profile, preventing abuse',\n",
       " '    The  Company  uses  a \\xe2\\x80\\x9cLigand Activated Therapy\\xe2\\x80\\x9d (\\xe2\\x80\\x9cLAT\\xe2\\x80\\x9d) discovery platform to create product candidates that offer improvements over FDA-approved and widely prescribed drugs',\n",
       " '    The 27 28  14 CLASS ACTION COMPLAINT \\x0cCase 3:16-cv-04605-WHO   Document 1   Filed 08/12/16   Page 15 of 24  1 projections  also  ignore  the  possibility  that  a  generic  drug  manufacturer  might  not  be  able  to 2 determine the process by which Relypsa manufactures Veltassa and therefore not have the ability 3 to obtain approval through an Abbreviated New Drug Application, which would have the effect 4 as  a  practical  matter  of  essentially  extending  the  exclusivity  period  as  a  generic  manufacturer 5 works  through  a  slower  drug  approval  process',\n",
       " '   10  \\x0cCase 3:17-cv-04830-JST   Document 1   Filed 08/18/17   Page 11 of 33Companies  may  not  promote  drugs  for  \\xe2\\x80\\x9coff-label\\xe2\\x80\\x9d  use\\xe2\\x80\\x94that  is,  uses  that  are  not described  in  the  product\\xe2\\x80\\x99s  labeling  and  that  differ  from  those  approved  by  the  FDA',\n",
       " '   Companies  may  not  promote  drugs  for  \\xe2\\x80\\x9coff-label\\xe2\\x80\\x9d  use\\xe2\\x80\\x94that  is,  uses  that  are  not described  in  the  product\\xe2\\x80\\x99s  labeling  and  that  differ  from  those  approved  by  the  FDA',\n",
       " '   Companies may not promote drugs for \\xe2\\x80\\x9coff-label\\xe2\\x80\\x9d use\\xe2\\x80\\x94that is, uses that are not described  in  the  product\\xe2\\x80\\x99s  labeling  and  that  differ  from  those  approved  by  the  FDA',\n",
       " '   Raptor\\xe2\\x80\\x99s  second commercial drug product, QUINSAIR\\xe2\\x84\\xa2 (investigationally named MP-376), is approved for sale in the European Economic Area and Canada, and was acquired by Raptor in October 2015',\n",
       " '   The abuse-deterrent properties incorporated into RexistaTM are designed to make the product unlikable and discourage or make it more difficult to manipulate for the purpose of abuse or misuse via common routes of administration  including:  ingestion  following  chewing,  licking  or   If  approved, crushing; RexistaTM  may  be  the  only  abuse-deterrent  oxycodone  product  with properties that may provide early warning of drug abuse if the product is manipulated or abused',\n",
       " '   \\xe2\\x80\\x9cWe look forward to bringing this study to its planned end point, as algenpantucel-L  has  the  potential  to  be  the  first  and  only FDA approved  drug  for  resected pancreatic cancer, providing additional treatment options to patients, their families and  physicians,\\xe2\\x80\\x9d  said Nicholas  N',\n",
       " '  As a development stage company, Puma currently has no sales or 22 revenues, and will not be able to generate revenues until one of their drug 23 candidates is approved by the FDA',\n",
       " '  Catalyst has observed that 3,4-Dap has been known to be effective in the treatment of LEMS for over 20 years and yet there is still no FDA approved version of this drug',\n",
       " '  Contrave was one  of the first drugs to gain FDA approval with the  help  of data obtained Iron, the interim analysis  of an ongoing trial',\n",
       " '  Food  and  Drug  Administration  (the  \\xe2\\x80\\x9cFDA\\xe2\\x80\\x9d)  is  the  federal government agency responsible for approval of drugs, including Specturm\\xe2\\x80\\x99s products',\n",
       " '  Food  and  Drug  Administration  in  which regulators told the company not to seek approval for a bladder cancer drug because two clinical trials failed to benefit patients',\n",
       " '  Food  and  Drug Administration  (the  \"FDA\")  is  the  federal  government agency  responsible  for  approval  of drugs,  including  Innocoll\\'s  products',\n",
       " '  Food  and  Drug Administration\\xe2\\x80\\x99s (\\xe2\\x80\\x9cFDA\\xe2\\x80\\x9d) would ultimately approve neratinib for the treatment of breast cancer;  (ii)  as  such,  Puma  had  overstated  the  drug\\xe2\\x80\\x99s  approval  prospects  and/or commercial viability; and (iii) as a result, Puma\\xe2\\x80\\x99s public statements were materially false and misleading at all relevant times',\n",
       " '  If approved, Rexista\\xc2\\xae may be the only abuse-deterrent oxycodone product with properties that may provide early warning of drug abuse if the product is manipulated or abused',\n",
       " '  In  order to  get  a  drug approved  by  the  FDA,  a  New  Drug  Application  (\"NOA\")  must  be  submitted  to  the  FDA  for review',\n",
       " '  In December 2014, PTC began submitting a rolling new drug application (NDA) to the FDA for the approval of Translarna in nonsense mutation DMD',\n",
       " '  In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, patients with 2nd or 3rd line (Xeloda\\xc2\\xae),  an metastatic colon cancer were randomized to receive capecitabine approved drug for metastatic colon cancer, at a dose of 825 mg/m 2  BID (total daily dose of 1650 mg/m 2) on days 1 to 14 every 21 days, plus either KRX-0401 (perifosine) or placebo at 50 mg daily ',\n",
       " '  In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, patients with 2nd or 3rd line metastatic colon cancer were randomized to receive capecitabine (Xeloda \\xc2\\xae), an approved drug for metastatic colon cancer, at a dose of 825 mg/m 2  BID (total daily dose of 1650 mg/m 2) on days 1 to 14 every 21 days, plus either KRX-0401 (perifosine) or placebo at 50 mg daily ',\n",
       " '  KIT-302  is  comprised  of  two  FDA  approved  drugs, celecoxib  (Celebrex\\xc2\\xae)  for  the  treatment  of  pain  caused  by  osteoarthritis  and amlodipine besylate, a drug designed to treat hypertension',\n",
       " '  Key elements of our strategy are to: \\xef\\x82\\xb7  develop combination products with clinical and commercial advantages in the treatment of hypertension and pain caused by osteoarthritis, based on a combination of existing drugs and obtain approval thereof from the FDA and other foreign regulatory authorities;      \\xef\\x82\\xb7  expand  our  line  of  therapeutic  candidates  through  the  acquisition  or  in-licensing  of  technologies,  products  and  drugs  intended  to  meet  clinical needs,  thereby  utilizing  the  skills,  knowledge  and  experience  of  our personnel  to  develop  and  enhance  the  value  of  additional  products,  and bring them to market efficiently;    7 \\x0cCase 1:17-cv-00917-LGS   Document 1   Filed 02/07/17   Page 8 of 20\\xef\\x82\\xb7  capitalize on the FDA\\xe2\\x80\\x99s 505(b)(2) regulatory pathway to obtain more timely and efficient approval of our formulations of previously approved products, when applicable;  and      \\xef\\x82\\xb7  cooperate with third parties to both develop and commercialize therapeutic candidates in order to share costs and leverage the expertise of others',\n",
       " '  Management characterized their ongoing pre-approval discussions with the FDA, including the drug label, as positive and constructive in a conversation we had last week',\n",
       " '  Nevertheless, approval of the drug for use in the United States creates significant growth opportunities',\n",
       " '  On June 24, 2011, the Company announced that a Complete Response Letter was received from the FDA regarding the resubmission of the NDA for REMOXY whereby the FDA delayed approval of the drug for a second time',\n",
       " '  On Wednesday,  a  panel  of  outside  experts  convened  by  the  FDA reviewed  the  apaziquone  clinical  data  and  decided  unanimously  the drug did not warrant approval',\n",
       " '  On that last point, Jacobus agrees, which is why the small drugmaker is in a race to get 3,4-Dap approved before Catalyst can do the same with Firdapse',\n",
       " '  Our strategy Our  goal  is  to  become  a  significant  player  in  the  development  of  innovative chemical drugs with a clinical and commercial added value, based on known and approved-for-use drugs',\n",
       " '  Specifically,  Defendants  failed  to  disclose  that:  (1)  Intellipharmaceutics  12 \\x0cCase 1:17-cv-05761-JPO   Document 1   Filed 07/28/17   Page 13 of 26failed to conduct a human abuse liability study to support its Rexista NDA; (2) the Company did not include abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of the drug by various pathways, including oral, intra-nasal and intravenous routes of abuse; (3)  Intellipharmaceutics  was  not  submitting  sufficient  data  to  support  approval  of  the  Rexista NDA; and (4) as a result of the foregoing, Defendants\\xe2\\x80\\x99 statements about Intellipharmaceutics\\xe2\\x80\\x99 business, operations, and prospects, were false and misleading and/or lacked a reasonable basis',\n",
       " '  Specifically, Defendants made false and/or misleading statements and/or failed to 3 \\x0cCase 1:17-cv-00145-EGS   Document 1   Filed 01/23/17   Page 4 of 22 disclose that Acthar\\xe2\\x80\\x99s monopoly status as the only FDA-approved ACTH preparation was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare  and  Medicaid  meant  that  the  Company\\xe2\\x80\\x99s  monopolistic  Acthar  revenue  would  be threatened if the government took action to limit the price paid for this drug by taxpayers',\n",
       " '  That\\xe2\\x80\\x99s  an  aggressive  timeline  but  one  that  could  secure  Stemline\\xe2\\x80\\x99s  first-ever cancer drug approval in 2018',\n",
       " '  The drug, thus, was  4 \\x0cCase 3:17-cv-00002-RP-HCA   Document 2-1   Filed 01/12/17   Page 5 of 31E-FILED  2016 NOV 04 4:31 PM JOHNSON - CLERK OF DISTRICT COURTapproved  to  manage  acute  pain,  but  would  not  be  able  to  be  sold  with  the  Company\\xe2\\x80\\x99s  main planned competitive advantage of labeling the drug as an \\xe2\\x80\\x9cabuse-deterring\\xe2\\x80\\x9d product',\n",
       " '  The drug, thus, was approved  to  manage  acute  pain,  but  would  not  be  able  to  be  sold  with  the  Company\\xe2\\x80\\x99s  main planned competitive advantage of labeling the drug as an \\xe2\\x80\\x9cabuse-deterring\\xe2\\x80\\x9d product',\n",
       " '  The statements in \\xc2\\xb6\\xc2\\xb6 20\\xe2\\x80\\x9341 above were materially false and/or misleading because they misrepresented and/or failed to disclose that: (i) the Company was overstating the efficacy of its Exparel drug; (ii) the Company was improperly promoting its Exparel drug by touting its ability to be effective for up to 72 hours, when in fact, it is approved only for 24 hours of pain relief; (iii) the Company improperly claimed that Exparel is safe for use in cholecystectomy and colectomy procedures, when in fact, approved labeling does not provide instructions for, or indicate that Exparel will be safe and effective for, postsurgical pain, if used in surgical procedures other than hemorrhoidectomy or bunionectomy; (iv) a substantial portion of the Company\\xe2\\x80\\x99s revenues were derived {00144416;1 } (cid:9)439040',\n",
       " '  This is a novel and highly innovative process that many had hoped would help give new drugs a more speedy approval without a substantial increase in risk',\n",
       " '  Throughout the Class Period, Defendants conditioned investors to believe that the Company\\xe2\\x80\\x99s drug Tivopath or tivozanib, for the treatment of advanced kidney cancer, would receive approval from the U',\n",
       " '  Thus, despite the fact that the six previous drugs which are approved 2 for early-stage breast cancer all submitted CART data prior to or simultaneously 3 with their NDA, Puma led investors to believe it could submit that data 4 subsequent to their NDA filing',\n",
       " '  We  have  conducted  studies  of SCY-078 using  animal  models  that  were  used  in  the  development  of  previously approved anti-fungal drugs where these models were proven to be predictive of efficacy  in  humans',\n",
       " '  Yes, so Jane, on your question related to accelerated approval, we believe these two drugs are very different, so in terms of will the FDA look differently upon our NDA submission in light of the drisapersen data, again, we think our data set is very differentiated, as I described earlier with our dystrophin analysis',\n",
       " '  Yuvvexy, the conditionally-approved trade name for the company\\xe2\\x80\\x99s TX-004HR drug  candidate,  is  an  applicator-free,  vaginal,  estradiol  softgel  capsule  being proposed  for  the  treatment  of  moderate-to-severe  vaginal  pain  during  sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause',\n",
       " '  \\xe2\\x80\\xa6 We anticipate submitting an administrative NADA [new animal drug application] by  the  end  of  March  2016,  which  if  approved,  is  expected  to  enable  us  to commence  commercialization  of  ENTYCE  in  the  United  States  in  late-2016 or shortly  thereafter',\n",
       " ' \"The BLISS-52 results demonstrated that BENLYSTA has the potential to become the first new approved drug in decades for people living with systemic lupus,\" said H',\n",
       " ' \"The BLISS-76 results confirm our view that BENLYSTA has the potential to become the first new approved drug in decades for people living with systemic lupus,\" said H',\n",
       " ' \"The European regulatory approval of our manufacturing facility is an important milestone for Isis and a validation of our high standards and excellence in manufacturing antisense drugs',\n",
       " ' \"They may lose the ability to get early approval  of drugs',\n",
       " ' \"We view the results of these studies as strongly supportive of our view that BENLYSTA has the potential to become the first new approved drug in more than 50 years for people living with systemic lupus',\n",
       " ' (cid:9)As such, during the Class Period, the Defendants made repeated misleadingly optimistic statements about EVOMELA, specifically touting it a future driver of the Company\\'s revenues, and repeatedly, falsely stating that the Company \"fully expected\" the FDA to approve the NDA by October 23,  2015, and that that the drug would likely be marketed by year end 2015 ',\n",
       " ' (cid:9)However, as part of the FDA approval process for Contrave, Orexigen 23 and Takeda Pharmaceutical Company Limited (\"Takeda\"), which is developing the 24 drug with Orexigen, were required to conduct \"a new randomized, double-blind, 25 placebo-controlled study to evaluate the effects of long-term treatment with Contrave 26 on the incidence of [major adverse cardiac events, or \\'MACE\\'] in overweight and 27 obese subjects with [cardiovascular] disease or multiple [cardiovascular] risk factors,\" 28 referred to as the \"LIGHT study',\n",
       " \" (cid:9)In the early afternoon of March  5,  2015,  Forbes published a report 13 14 quoting various stock analysts and drug development experts speculating that the 15  Company's now repeated early disclosure of interim trial data could potentially 16 threaten its relationship with the FDA and its ability to obtain further drug approvals 17 with the agency\",\n",
       " ' (cid:9)The Registration Statement represented that \"[w]e have the ability to manufacture our own botulinum toxin type A product to support our clinical trials\" and \"currently manufacture our own clinical drug products to support both RT001 and RT002 exclusively in a single manufacturing and laboratory facility and plan to utilize this facility in the future to support commercial production if our product candidates are approved',\n",
       " \" *** SARAH SUBCOMB: Maybe piggybacking off of that question a little bit, you've got a bunch of other exon targeting drugs in your pipeline and you've spoken about dystrophin as being an eventual surrogate for kind of a class approval for all these drugs\",\n",
       " ' 19 20 Subsequently, the Company received a Complete Response Letter from the FDA in January 2013, 21 indicating that the Company had failed to win approval for its drug RYTARY',\n",
       " ' 2  If the drug usage is officially indicated they are \"FDA approved\" (also called \\'labeled\\') and if it is prescribed or taken outstanding to its applied indications the term \"Non-approved\" (or \\'off-label\\') is used',\n",
       " ' 21 \\xc2\\xa7\\xc2\\xa7301-97, manufacturers are prohibited from directly marketing a drug for a use other than the FDA approved indication',\n",
       " ' 24 (cid:9)Though drug developers are not required to obtain FDA consent of the design of their Phase 3 clinical trials, because Phase  3  clinical trials involve hundreds of people and take years to COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS -8- \\x0cCase3:15-cv-02512-HSG Document1-2 Filed06/05/15 Page11 of 61  complete, making them very expensive, the FDA permits drug developers/sponsors to sit down with the 2 agency following the conclusion of a Phase 2 trial to ensure that the size, design and endpoints selected 3 for a Phase 3 clinical trial will demonstrate what the FDA requires for approval According to the 4  agency, \"[a]t the end of Phase 2, the FDA and sponsors try to come to an agreement on how large-scale studies in Phase 3 should be done,\" and \"Phase 3 studies [then] begin if evidence of effectiveness is 5 6 shown in Phase 2',\n",
       " ' 25 Orphan drug designation provides United States marketing exclusivity for seven 26 years if approval is received from the FDA, in addition to certain tax benefits for 27 qualifying expenses',\n",
       " ' A follow up question was presented by Adnan Butt (\"Butt\") with RBC Capital Markets as follows: I wanted to ask on Poziotinib, you mentioned the Phase 2 study, when could it start and what types of breast cancer patients would you enroll, would it be a similar population to the prior study? And then on EVOMELA, how quickly could you launch assuming approval, post-approval? Shrotriya answered as follows: Let me talk about EVOMELA, as soon as the approval comes, we plan to launch this drug as soon as possible, it may take a couple of months, but I would think that we should be able to launch quickly after approval',\n",
       " ' A priority review designation is granted to drugs that, if approved, offer major advances in treatment or provide a treatment where no adequate therapy exists',\n",
       " ' ACADIA has a pipeline of product candidates led by NUPLAZID (pimavanserin), for which the Company reported positive Phase III trial results as a treatment for PDP and which has the potential to be the first drug approved in the United States for this disorder',\n",
       " ' Accordingly, Defendant Macdonald continued to tout the efficacy and outlook of Eravacycline and imply the drug would most likely be approved by the FDA by year-end 2015',\n",
       " ' Acthar Gel (Repository Corticotropin Injection) (\"Acthar\"), an 2  injectable drug that is approved by the U',\n",
       " ' Acthar, a highly specialized, low-volume, premium-priced drug, 9 was originally approved by the FDA in  1952',\n",
       " ' Additionally, the FDA has withheld and may continue to withhold approval of pending drug applications listing our Hayward, California facility as a manufacturing location of finished dosage forms until these FDA observations are resolved',\n",
       " ' After years of supplying 3,4-Dap for free through compassionate use programs, Jacobus decided to conduct its own clinical trial with the intent of getting the drug formally approved by the FDA',\n",
       " ' And given where we are in the enrollment phase,  we anticipate study completion to occur in the fourth quarter of this year, taking [] into account that we have fast track designation for this compound, we\\xe2\\x80\\x99re looking at a potential drug approval for perifosine in metastatic colorectal in the year 2012',\n",
       " ' And the understanding \\xe2\\x80\\x93 the FDA said that if we approve your drug now, or review your drug application now, there is no way you can complete a placebo-controlled trial',\n",
       " ' Around the same time, in January 2012, Vertex gained approval for the drug Kalydeco',\n",
       " ' As Joe mentioned, there\\xe2\\x80\\x99s is a dearth of new therapies, and apaziquone has the potential to be the first new drug approved to treat nonmuscle-invasive bladder cancer in more than 40 years',\n",
       " ' As a reminder, niacin is an HDL-raising drug, not a triglyceride lowering drug, and niacin remains approved and on the market',\n",
       " ' At present, no drug has received FDA approval to treat CFS, a chronic, seriously debilitating disease',\n",
       " ' At the meeting FDA expressed willingness to work with Provectus toward initial approval for the novel investigational oncology drug PV- 10 in locally advanced cutaneous melanoma',\n",
       " ' Because it would render us unable to get other drug approved for the rare exon, because we would not be able to power studies on a 6-minute walk or these other endpoints',\n",
       " \" Because the two compounds that comprise Orexigen have been previously approved and are no longer on patent Orexigen's intellectual property is based on the novel application of t1ie drug combination to reduce weight\",\n",
       " ' But a law called the Orphan Drug Act (\"ODA\") provides seven years of exclusive sales rights to manufacturers who win FDA approval for drugs that affect fewer than 200,000 people',\n",
       " ' But key to the bull case for Esperion is whether the FDA will require the company to run a long, costly safety study before approving its cardio drug',\n",
       " ' Companies may not promote drugs for \"off-label\" use\\xe2\\x80\\x94that is, uses that are not described  in  the  product\\'s  labeling  and  that  differ  from  those  approved  by  the  FDA',\n",
       " ' Companies may not promote drugs for \\xe2\\x80\\x9coff-label\\xe2\\x80\\x9d use\\xe2\\x80\\x94that is, uses that are not described  in  the  product\\xe2\\x80\\x99s  labeling  and  that  differ  from  those  approved  by  the  FDA',\n",
       " ' Compassionate use programs allow seriously ill patients who meet certain criteria to gain access to investigational drugs that have not yet been approved by the FDA',\n",
       " ' Currently approved drugs for BPH can produce significant sexual side effects',\n",
       " ' Currently, there are no drugs approved for the treatment of NASH',\n",
       " ' Defendant Incyte is a Wilmington, Delaware based pharmaceutical company with one drug approved by the FDA for distribution and sale in the United States, Jakafi (ruxolitinib), which received approval in November 2011',\n",
       " ' Don\\xe2\\x80\\x99t forget in the last 40 years no drug has been approved for nonmuscle invasive bladder cancer',\n",
       " ' During this conference call, Defendant Finizio stated, in relevant part: On July 7, we submitted our new drug application, also known as an NDA, for TX-004HR or Yuvvexy, our conditionally-approved trade name',\n",
       " ' Egalet designed a pharmacokinetic development program for ARYMO ER aiming to  demonstrate  its  bioequivalence  to  a  direct  competitor\\xe2\\x80\\x99s  already  approved  drug  named  MS   7 \\x0c  Case 2:17-cv-00390-MMB   Document 1   Filed 01/27/17   Page 8 of 23 Contin',\n",
       " ' Egalet submitted a New Drug Application (\\xe2\\x80\\x9cNDA\\xe2\\x80\\x9d) to the United States Food and Drug Administration (\\xe2\\x80\\x9cFDA\\xe2\\x80\\x9d) for ARYMO ER in December 2015 based on studies aiming to demonstrate  its  bioequivalence  to  a  direct  competitor\\xe2\\x80\\x99s  already  approved  drug  named  MS Contin',\n",
       " ' Enrollment is expected to be completed by the end of June this year and top-line results will be available in the fourth quarter of this year with potential drug approval in the US in 2012',\n",
       " ' FDA could have approved eteplirsen, the thinking went, and then design some kind of study that allowed it to confirm the drug\\xe2\\x80\\x99s efficacy \\xe2\\x80\\x93 perhaps, Sarepta was suggesting, comparing boys on eteplirsen to those whose Duchenne was caused by a different mutation, preventing any boy who could benefit from having to get placebo',\n",
       " ' FDA drug approval to market Triferic (ferric pyrophosphate citrate), the only iron replacement and hemoglobin maintenance product for hemodialysis patients',\n",
       " ' FUSILEV has been designated as an orphan drug for its approved indications',\n",
       " ' Federal Drug Administration\\xe2\\x80\\x99s (\\xe2\\x80\\x9cFDA\\xe2\\x80\\x9d) regulatory function,interstate distribution of adulterated and unapproved new drugs, making false statements to theFDA and obstruction of an FDA inspection',\n",
       " ' Food & Drug Administration (the \\xe2\\x80\\x9cFDA\\xe2\\x80\\x9d) has approved its drug Triferic \\xc2\\xae  (\\xe2\\x80\\x9cTriferic\\xe2\\x80\\x9d) for commercial sale, and touting Triferic\\xe2\\x80\\x99s ability to become the market-leading therapy for hemodialysis patients combating chronic kidney disease',\n",
       " ' Food and Drug 18 Administration (\\xe2\\x80\\x9cFDA\\xe2\\x80\\x9d) approval for RYTARY TM  (\\xe2\\x80\\x9cRytary\\xe2\\x80\\x9d), an extended-release drug for 19 treatment of Parkinson\\xe2\\x80\\x99s disease',\n",
       " ' Food and Drug Administration (\"FDA\") approval for distribution and sale of just one of its drug offerings in the United States, Jakafi (ruxolitinib), which the FDA first approved for sale in November 2011',\n",
       " ' Food and Drug Administration (\"FDA\") granted accelerated approval of one of Chelsea\\'s licensed drugs, droxidopa, which goes by the trade name \"Northera',\n",
       " ' Food and Drug Administration (FDA) 28 warning letter regarding the Hayward site including obtaining approval of the Company\\xe2\\x80\\x99s New Drug COMPLAINT 7 (cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)\\x0cCase3:14-cv-03673-JD Document1 Filed08/13/14 Page9 of 24  Application for an investigational drug, RYTARY',\n",
       " ' Food and Drug Administration for Yuvvexy, the conditionally approved trade name for TX-004HR,  the  company\\xe2\\x80\\x99s  applicator-free  vaginal  estradiol  softgel drug  candidate  for the  treatment  of  moderate-  to-severe  vaginal  pain during  sexual  intercourse  (dyspareunia),  a  symptom  of  vulvar  and vaginal atrophy (VVA) due to menopause',\n",
       " ' For example, these materially false and misleading statements included, among others, that PNT2258: \\xef\\x82\\xb7  \\xe2\\x80\\x9c[H]as the potential to change treatment paradigms across a wide range of oncology indications\\xe2\\x80\\x9d;   Is at the \\xe2\\x80\\x9cforefront of DNAi-based therapies\\xe2\\x80\\xa6[and] the only product candidate in clinical testing using this novel approach\\xe2\\x80\\x9d;  Is  envisioned  \\xe2\\x80\\x9cto  deliver  extraordinary  therapeutic  outcomes  that  dramatically change patients\\xe2\\x80\\x99 lives\\xe2\\x80\\x9d;  \\xef\\x82\\xb7 \\xef\\x82\\xb7 \\xef\\x82\\xb7  Uses  a  unique  propriety  technology  which  \\xe2\\x80\\x9cmay  allow  [it]  to  more  profoundly impact oncogenic targets that may be difficult to effectively drug with these other approaches,  and  potentially  result  in  enhanced  efficacy,  durability  and  safety outcomes\\xe2\\x80\\x9d;  \\xef\\x82\\xb7 \\xef\\x82\\xb7 Is  a  unique  propriety  technology  that  \\xe2\\x80\\x9ccould  also  potentially  amplify  and  be complementary to other therapeutic modalities\\xe2\\x80\\x9d; and Is being clinically developed pursuant to a Company strategy \\xe2\\x80\\x9cthat is designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258',\n",
       " ' For example:  (a) on July 13, 2012, a unit of the Company received its first FDA approval of the  100 mg, 200 mg, and 300 mg tablets of its generic version of the drug Trandate;  (b) on April 19, 2012, the Company announced that it entered into an exclusive  acquisition and licensing agreement with Handa Pharmaceuticals LLC to acquire Handa\\xe2\\x80\\x99s ANDA  for dexlansoprazole capsules, which is the generic version of Takeda\\xe2\\x80\\x99s Dexilant',\n",
       " ' Further, the Warning Letter noted that a journal ad by Pacira touted Exparel as being able to provide pain-relief for up to 72 hours, while the drug is approved for pain-relief only up to 24 hours',\n",
       " ' Further, the Warning Letter noted that a journal advertisement by Pacira claimed Exparel was able to provide pain-relief for up to 72 hours, while the drug is approved for pain-relief only up to 24 hours',\n",
       " ' Given the fact that the 360th event will trigger the completion of the study, we expect that that will happen in the fourth quarter of 2011we have fast-track designation for perifosine in multiple myeloma, we are looking at a potential drug approval in metastatic colorectal in the year 2012 for this compound',\n",
       " ' Given the lack of new therapies for these patients, Apaziquone has the potential to be the first new drug approved to treat non-muscle-invasive bladder cancer in more than 40 years',\n",
       " ' He continued, \"[w]ith the potential approval of Evomela in October, we could have six drugs on the market',\n",
       " ' However, device and drug manufacturers such as Medtronic cannot actively promote products for uses not approved by the FDA',\n",
       " ' However, if we obtain FDA approval for, and start  marketing,  our  own  CNS  brand-name  pharmaceuticals,  we  expect  that competition  will  be  limited  to  large  pharmaceutical  companies,  other  drug delivery  companies,  and  other  specialty  pharmaceutical  companies  that  have focused on CNS disorders',\n",
       " ' However, we know that many patients had put a lot of hope into our ability to convince the FDA that the drug deserves early approval, and had expectations that with the potential NDA filing in the first half 2014, that the possibility of an eteplirsen FDA approval could have come in late 2014 or early 2015',\n",
       " \" I've heard that the dating for approval on April 28 last year, when we got approval, 7- \\x0cCase 2:13-cv-00433-LDG-CWH Document 1 Filed 03/14/13 Page 9 of 23 somebody put out a blog saying that this drug is going to be - Spectrum is going to go down the hill and we lost a huge market cap on that day, on a day when we got approval for FUSILEV\",\n",
       " ' If approved by the FDA, SER-109 would be, according to the Company, \\xe2\\x80\\x9ca first-in-field drug',\n",
       " ' If found sufficient to support approval of the drug, these new analyses will be in lieu of an additional confirmatory Phase III study called for in the Agency\\'s November  25,  2009, Complete Response Letter (\"CRL\") ',\n",
       " \" If found sufficient to support approval of the drug, these new analyses will be in lieu of an additional confirmatory Phase III study called for in the FDA's November  25, 2009 CRL\",\n",
       " ' In 2009, K-V and its subsidiaries, Ther-Rx and ETHEX, entered into a consent decree for making and distributing adulterated and unapproved drugs',\n",
       " ' In May we received a positive opinion from the CHMP for marketing approval for TranslarnaTM (ataluren) an CLASS ACTION COMPLAINT 6 \\x0cCase 2:16-cv-01224-KM-MAH Document 1 Filed 03/03/16 Page 8 of 43 PageID: 8  investigational new drug in the US, for nonsense mutation Duchenne muscular dystrophy and we recently received the approval from the European Commission granting the conditional marketing authorization',\n",
       " ' In addition, evidence at the trial of Hedviga Herman, Halsey\\xe2\\x80\\x99sformer Vice-President of Manufacturing, showed that Halsey added unapproved ingredients tocertain drugs and falsified records to cover up those additions',\n",
       " ' In addition, since approval of Auryxia in 2014, Keryx has been working  to  bring  a  secondary  manufacturer  online  to  supply  finished  drug product',\n",
       " ' In addition, the Company Board discussed with Deutsche Bank and Torreya the history of midodrine, the only other currently approved drug for the treatment of orthostatic hypotension and certain projections prepared by management of the Company assuming that midodrine was taken off the market or would have a restriction for use added to its label by the FDA (the \"no-midodrine case\")',\n",
       " ' In fact, last year alone, there were at least five newly approved orphan drugs priced at least $150,000 per patient per year, with three priced at or above $300,000 per patient per year',\n",
       " ' In order to gain approval for such combination drugs, the FDA requires that the applicant performs a study which demonstrates that the combination of the drug provides a direct benefit over the individual components when those individual components are 5  \\x0cCase 1:15-cv-04868-PAE Document 1 Filed 06/23/15 Page 6 of 26  employed at equivalently potent dosages',\n",
       " ' In order to get a drug approved by the FDA, a New Drug Application (\\xe2\\x80\\x9cNDA\\xe2\\x80\\x9d) must be submitted to the FDA for review',\n",
       " ' In relevant part, Defendant Finizio stated: On July 7, we submitted our new drug application for Yuvvexy, the conditionally approved  trade  name  for  TX-004HR,  reflecting  a  major  achievement  for  our company',\n",
       " \" In response to a question regarding KangioTM's FDA action date and expectations to launch the drug, Defendant Tarriff responded: We are in dialogue with FDA, as you would expect coming down to the final weeks before approval\",\n",
       " ' In the 2015 20-F, Kitov stated, in part: On December 15, 2015, we announced that the Phase III, double-blind, placebo-controlled clinical trial for our leading drug candidate, KIT-302, successfully met the primary efficacy endpoint of the trial protocol as approved by the FDA',\n",
       " ' In the BPH studies to date, a single dose of NX- 1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs',\n",
       " ' In the BPI-I studies to date, a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved 7 \\x0cCase 2:14-cv-07331-JLL-JAD Document 1 Filed 11/24/14 Page 8 of 23 PageID: 8  BPI-I drugs without causing the sexual or cardiovascular side effects associated with those drugs',\n",
       " ' In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, patients with 2nd or 3rd line metastatic colon cancer were 19 \\x0cCase 1:13-cv-00755-UA Document 1 Filed 02/01/13 Page 23 of 153  (Xeloda\\xc2\\xae),  an approved drug for metastatic colon randomized to receive capecitabine cancer, at a dose of 825 mg/m2 BID (total daily dose of 1650 mg/m2) on days 1-14 every 21 days, plus either perifosine or placebo at 50 mg daily',\n",
       " ' In this unmet medical need, no drug has been approved in the space',\n",
       " \" It's also important to remember that there is currently no drug approved by FDA for use as a high dose conditioning agent for these patients with multiple myeloma\",\n",
       " \" It's hard to imagine a scenario under which Hernispherx's stock would have almost tripled in value and $9 million could have been raised from investors had the company disclosed publicly the FDA's warning that Ampligen data submitted wasn't likely sufficient to get the drug approved\",\n",
       " ' Its top-selling drug is XIFAXAN\\xc2\\xae (rifaximin) (\"Xifaxan\"), an antibiotic that is currently approved to treat a condition referred to as \"traveler\\'s diarrhea\" and a liver disorder that impairs brain function',\n",
       " ' Kalydeco, which in January became the first drug approved to treat the underlying cause rather than symptoms of the serious lung disease, helps about 4 percent of CF patients with a specific gene mutation',\n",
       " ' KemPharm is a clinical-stage specialty pharmaceutical company engaged in the discovery  and  development  of  proprietary  prodrugs  that  KMPH  believes  will  be  improved versions  of  widely  prescribed,  approved  drugs',\n",
       " ' Look, we know that, when you approve drugs on the basis of a surrogate like dystrophin, that the FDA will likely want sponsors to follow those patient postmarketing',\n",
       " ' McEnany responded via email: Catalyst is seeking to develop this drug in order to make an FDA approved treatment available to all patients suffering from LEMS in a relatively short period of time',\n",
       " ' No new drug for lupus has been approved by regulatory authorities in more than 50 years',\n",
       " ' Notably,  in  September  2014  the  Company  reached  an  agreement  with  the  FDA regarding a SPA on the design, endpoints and statistical analysis approach of a Phase III trial for TG-1101 in combination with ibrutinib, a drug already approved by the FDA, for the treatment of CLL in patients with high risk cytogenetics',\n",
       " ' On April 1, 2011, defendants issued a press release that stated in relevant part: As part of its ongoing efforts to ensure that high-risk women have access to FDA-approved Makena instead of unapproved, unregulated compounded drugs, Ther-Rx Corporation, a subsidiary of K-V Pharmaceutical Company (NYSE: KVa/KVb) (the \"Company\"), announced today important initiatives to reduce the cost of M akenaTM (hydroxyprogesterone caproate injection) and encourage stakeholders to provide timely access to this important FDA-approved medication',\n",
       " ' On January 21, 2013, Impax issued a press release announcing that it had failed to win approval for its drug Rytary, as the FDA was requiring a satisfactory re-inspection of the Company\\xe2\\x80\\x99s Hayward facility as a result of the May 2011 warning letter before the Company\\xe2\\x80\\x99s NDA could be approved given the facility\\xe2\\x80\\x99s involvement in the development and manufacturing of Rytary',\n",
       " ' Once approved, we plan to launch this drug using our existing sales force',\n",
       " ' One analyst asked defendant Auerbach whether the Company knew that the changed primary indication would cause the FDA to ask for additional data that the company didn\\xe2\\x80\\x99t have:  <Q -  [Analyst]>:  So let me ask you, I mean, I understand that the six previous drugs which are approved for early-stage breast cancer, submitted their CART data either, as you noted, ahead of time, or at the time of NDA filing',\n",
       " ' One possibility is for the FDA to withdraw approval of the drug after concluding that the company is now unable tofiilfihl the post-approval requirement that it study the CVsaftty of Contrave',\n",
       " ' Only recently, the Company received FDA approvals, acquired  ANDAs from other pharmaceutical companies, and began shipping generic versions of several   lucrative drugs',\n",
       " ' Patients enrolled have failed all approved drugs and regiments like (inaudible) and other (inaudible) and if they are (inaudible) type, then they will have failed also in treatment with EGFR antibodies, for instance Erbitus and Vectibix',\n",
       " ' Perhaps most importantly, the company press release on December 18, 2013 clearly stated that our company held a Type C meeting (not an End of  Phase  2 meeting) with the FDA on December 16, 2013 \"to determine which of the available paths that Provectus\\' novel oncology drug PV-10 will take in pursuit  o f FDA approval and commercialization',\n",
       " ' Phase 1: Once an JND has been approved by the FDA, drug candidates first undergo a Phase 1 clinical trial which typically involves  20 to 100 healthy volunteers and lasts several months According to the FDA, the purpose of Phase 1 clinical testing is to determine safety and dosage, and  70% of all drug candidates successfully complete this phase Phase 2: Phase 2 clinical trials typically involve up to several hundred people with the disease or condition and last several months to two years',\n",
       " ' Phase III is the usually the last stage of clinical trials leading up to approval or disapproval of the drug',\n",
       " ' RYTARY, also known as IPX066, is the first drug that Impax sought to take 4 through the entire FDA approval process for a new pharmaceutical',\n",
       " ' Regarding packaging, prior to submitting our NDA to the FDA, for Triferic drug approval, we created a more efficient and more cost-effective way to package Triferic',\n",
       " ' Rytary, also known as IPX066, is the first drug that Impax sought to take 27 through the entire FDA approval process for new drugs',\n",
       " ' Shainfeld and Marcus sanctionedthe falsifications Citing Halsey\\xe2\\x80\\x99s June 21, 1993 plea of guilty to a five-count criminal informationcharging that in September 1992, Halsey shipped adulterated drugs in interstate commerce,specifically admitting that it failed to comply with CGMP by causing the preparation andmaintenance of false production records and caused the manufacture of a certain drug using anon-FDA approved formula ( United States v',\n",
       " ' Shainfeld eventually admitted he and others atHalsey created and gave to the FDA inspectors records that fraudulently misrepresented certainresearch and development batch sizes that the FDA required to ensure that a company can, infact, manufacture production quantities of a drug according to the approved formula In reality, Halsey had been making smaller batches, then falsely claiming theywere the required size',\n",
       " ' Shrotriya never indicated that there could be a problem with approval of the NDA and in fact, gave the opposite impression - that the drug would likely be marketed by the end of the year',\n",
       " ' Since  July  15,  2015,  Pronai  and  certain  of  its  officers  and  directors  have misrepresented the efficacy and safety of PNT2258, and the drug\\xe2\\x80\\x99s purported attendant capacity  2 \\x0cCase 1:16-cv-08703-PAE   Document 1   Filed 11/09/16   Page 3 of 24for approval by the FDA',\n",
       " ' So we believe, not only the fact that FUSILEV got approval in 2011 as compared to generic leucovorin approval of 1952, the fact that ZEVALIN has a unique geno code should clearly tell people who are educated enough to understand the marketing and selling of oncology drugs, that it is differentiated product and it has nothing to do with generic leucovorin',\n",
       " \" So we know that the answers will be there eventually, even in the rare genetic subtypes, but that it's not a reason to stop access to these drugs and commercial approval of these drugs because we can't enroll enough patients to find a clinical benefit\",\n",
       " ' Specifically,  Defendants  made  false  and/or  misleading  statements  and/or  failed  to disclose that: (i) the Company did not anticipate that the FDA would ultimately approve neratinib for the treatment of breast cancer; (ii) as such, Puma had overstated the drug\\xe2\\x80\\x99s approval  prospects  and/or  commercial  viability;  and  (iii)  as  a  result,  Puma\\xe2\\x80\\x99s  public statements were materially false and misleading at all relevant times',\n",
       " ' Specifically, Defendants made false and/or misleading statements 1 2   and/or failed to disclose: (1) that the Instructions for Use (IFU) for Zalviso were not designed to 3   I  adequately address the risk of the inadvertent misplacement of tablets; (2) that the Company had 4   not submitted to the FDA sufficient data to support the shelf life of the product; and (3) that, as a 5  result of the foregoing, Defendants\\xe2\\x80\\x99 statements about Zalviso, including the drug\\xe2\\x80\\x99s regulatory 6    approval and financial prospects, were materially false and misleading at all relevant times 7 8   and/or lacked a reasonable basis',\n",
       " ' Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Scynexis\\xe2\\x80\\x99s lead product candidate, SCY-078, entailed substantial undisclosed health and safety risks; (ii)  2 \\x0cCase 2:17-cv-01565-KSH-CLW   Document 1   Filed 03/08/17   Page 3 of 27 PageID: 3consequently, the Company had overstated the drug\\xe2\\x80\\x99s approval prospectus and/or commercial viability; and (iii) as a result of the foregoing, Scynexis\\xe2\\x80\\x99s public statements were materially false and misleading at all relevant times',\n",
       " ' Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Scynexis\\xe2\\x80\\x99s lead product SCY-078 entailed substantial undisclosed health and safety risks; (ii) consequently, the Company had overstated the drug\\xe2\\x80\\x99s approval prospectus and/or commercial viability; and (iii) as a result of the foregoing, Scynexis\\xe2\\x80\\x99s public statements were materially false and misleading at all relevant times',\n",
       " ' Specifically, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was overstating the efficacy of its Exparel drug; (ii) the Company was improperly promoting its Exparel drug by touting its ability to be effective for up to 72 hours, when in fact, it is approved only for 24 hours of pain relief; (iii) the Company improperly claimed that Exparel is safe for use in cholecystectomy and colectomy procedures, when in fact, its approved labeling does not provide instructions for, or indicate that Exparel will be safe and effective for, postsurgical pain, if used in surgical procedures other than hemorrhoidectomy or bunionectomy; (iv) a substantial portion of the Company\\xe2\\x80\\x99s revenues were derived from off label marketing; and (v) and as a result of the above, the Company\\xe2\\x80\\x99s financial statements were materially false and misleading at all relevant times',\n",
       " ' Specifically, these are patients that have failed all approved drugs and regimens FOLFIRI, FOLFOX, Avastin',\n",
       " ' Still plan to enroll our confirmatory study, and of course, we are disappointed that a potential treatment has been hampered and may affect the timing or even the possibility of pursuit for an approval of that drug',\n",
       " ' TG Therapeutics continued its GENUINE Phase III trial in 2015 and 2016, even though  the  Company  was  rapidly  facing  patient  enrollment  issues,  leading  the  Company eventually, on October 13, 2016, to eliminate the primary endpoint of the study, losing the SPA  8 \\x0cCase 1:17-cv-00112-VM   Document 1   Filed 01/06/17   Page 9 of 27negotiated with the FDA, cutting planned enrollment to 120 patients and highly increasing the risk of disapproval of the drug by FDA',\n",
       " ' Taken together, these data have demonstrated that ITI-007 reduced psychosis in patients  with  schizophrenia  at  relatively  low  levels  of  striatal  D2  receptor occupancy,  lower  than  the  occupancy  range  required  by  most  drugs  currently approved  for  the  treatment  of  schizophrenia',\n",
       " ' That decree prohibited K-V from making or shipping drugs until the Company received FDA approval',\n",
       " ' The  SPA  provides  agreement  that  the  Phase  3  trial design  adequately  addresses  objectives  that  would  support  the regulatory submission for drug approval',\n",
       " ' The Advisory Committee, after hearing testimony and deliberating on Amarin\\xe2\\x80\\x99s application, voted 9-2 to reject the NDA for ANCHOR, adopting the FDA\\xe2\\x80\\x99s position that the ANCHOR study itself was not indicative of the efficacy of the drug to reduce severe cardiovascular events, and that the FDA should wait for completion of the REDUCE-IT study before approving Vascepa for the ANCHOR indication',\n",
       " ' The Company attempts to build long-term collaborations with pharmaceutical and biotechnology companies seeking to utilize its purported innovative and highly differentiated devices to enable or enhance the clinical development, regulatory approval and lifecycle where they can be integrated into the filling and packaging processes utilized for a target injectable drug or vaccine',\n",
       " ' The Company has never received approval for and commercialized a drug compound',\n",
       " \" The EMA's approval of the Isis manufacturing facility allows Isis to supply Genzyme with  KYNAMROTM  drug substance to support commercial launch in Europe\",\n",
       " \" The FDA approved Questcor's orphan drug status application in 26 October 2010\",\n",
       " ' The FDA offers  a  shortened  regulatory  procedure  referred  to  as  a  \\xe2\\x80\\x9c505(b)(2)  NDA\\xe2\\x80\\x9d  to approve combination drugs',\n",
       " ' The Galectin drug was granted FDA fast-track approval nearly a year ago',\n",
       " ' The Galeetin drug was granted FDA fast-track approval nearly a year ago',\n",
       " ' The NDA will be CLASS ACTION COMPLAINT 15 \\x0cCase 1:16-cv-01044-PAE Document 1 Filed 02/10/16 Page 17 of 37  based primarily on data from the PERSIST-1 Phase 3 trial \\xe2\\x80\\x94as well as data from Phase 1 and 2 studies of pacritinib\\xe2\\x80\\x94and additional information requested by the FDA, including a separate study report and datasets for the specific patient population with low platelet counts of less than 50,000 per microliter (<50,000/uL) for whom there are no approved drugs',\n",
       " ' The advisers will hear arguments from the company on why the experimental drug Ampligen should be approved for sale in the US',\n",
       " ' The best  solution  is clearly an FDA approved drug',\n",
       " ' The discussion with the FDA are proceeding well and if approved, EVOMELA will become our sixth commercial drug that will be launched with our existing sales force\" 50',\n",
       " ' The drug is not FDA approved here, so Catalyst is conducting a phase III study in LEMS patients (Biomarin started the study, Catalyst took it over) with top-line results expected in the middle of 2014',\n",
       " \" The first interim analysis, which took place in November 2013 after 25%  of the trial's endpoint events had occurred played an important role in helping the FDA decide to approve the drug in 2014\",\n",
       " ' The first step is the submission of a New Drug Application by a sponsor which is essentially a request by the sponsor asking the FDA to consider approving a new drug for a particular disease',\n",
       " ' The grounds for suspension of the SPA are precisely the same grounds that Amarin was apprised of by the FDA at the pre-NDA meeting in July 2008 (quoted  supra at Paragraph 28), that would require the completion of the REDUCE-IT outcomes, study prior to approval of the ANCHOR indication, as follows: 177986-1 (cid:9)- 18 - \\x0cCase 3:13-cv-06663-FLW-TJB Document 1 Filed 11/01/13 Page 19 of 24 PageID: 19  the Division noted [in July 2008] that there was a lack of prospective, controlled clinical trial data demonstrating that pharmaceutical reduction of non-HDL-C (or TG) with a second drug, in patients with elevated TG Levels at LDL goal on statin therapy, significantly reduces residual cardiovascular risk',\n",
       " ' The increase primarily results from additional costs associated with clinical trials including the manufacturing of drug product for our clinical trials and regulatory costs associated with the efforts to obtain conditional approval for Translarna in Europe',\n",
       " ' The potential breakthrough cancer drug is being evaluated under the EMA\\xe2\\x80\\x99s \\xe2\\x80\\x9cGuideline on Evaluation of Anticancer Medicinal Products in Man,\\xe2\\x80\\x9d which offers the possibility to establish novel approval endpoints for anti-cancer agents',\n",
       " ' The primary endpoint was the CAARS-INV, a widely accepted clinical measure of the presence and severity of ADHD symptoms, which has been utilized in registration studies for other approved ADHD drugs',\n",
       " ' The prospectus again touted CHMP\\'s \"positive opinions\" for the \"Conditional Marketing Authorisations of VYNFINIT\\xc2\\xae (vintafolide)\" and further boasted that if the opinion is approved by the European Commission, the -10- \\x0cCase 1:14-cv-01048-TWP-MJD Document 1 Filed 06/24/14 Page 11 of 19 PageID #: 11  drug could soon go on sale in twenty-eight countries',\n",
       " \" The purpose of the meeting was to determine which of the available paths that Provectus' novel oncology drug PV- l 0 will take in pursuit of FDA approval and commercialization\",\n",
       " ' The research, testing, manufacturing, labeling, approval, commercialization, marketing, selling and distribution of drug products are subject to regulation by state authorities and the FDA in the United States and other regulatory authorities in other countries, with regulations differing from country to country',\n",
       " ' The statements contained in \\xc2\\xb6\\xc2\\xb621-28 were materially false and/or misleading when made because defendants failed to disclose or indicate the following: (1) that the Instructions for Use (IFU) for Zalviso were not designed to adequately address the risk of the inadvertent misplacement of tablets; (2) that the Company had not submitted to the FDA sufficient data to support the shelf life of the product; and (3) that, as a result of the foregoing, Defendants\\xe2\\x80\\x99 statements about Zalviso, including the drug\\xe2\\x80\\x99s regulatory approval and financial prospects, were materially false and misleading at all relevant times and/or lacked a reasonable basis 31',\n",
       " ' The statements contained in \\xc2\\xb6\\xc2\\xb631-32 were materially false and/or misleading when made because defendants failed to disclose or indicate the following: (1) that the Instructions for Use (IFU) for Zalviso were not designed to adequately address the risk of the inadvertent misplacement of tablets; (2) that the Company had not submitted to the FDA sufficient data to support the shelf life of the product; and (3) that, as a result of the foregoing, Defendants\\xe2\\x80\\x99 statements about Zalviso, including the drug\\xe2\\x80\\x99s regulatory approval and financial 292737',\n",
       " ' The statements referenced above in  \\xc2\\xb61120-29  were each materially false and misleading because they failed to disclose and misrepresented the following adverse facts which were known to defendants or recklessly disregarded by them: (a) Incyte\\'s reported 4Q2011 and 1Q2012 sales had been artificially inflated due to a large number of extremely sick, advanced-stage myelofibrosis patients being prescribed Jakafi initially upon FDA approval in November 2011 - patients who had been too sick to participate in the clinical trials - and its revenues were dropping in 2Q 2012 as these patients expired and quit using the drug; (b) Incyte\\'s Class Period drug dropout rates were not comparable to those achieved during the clinical trials because the more sickly, advanced patients were excluded from the clinical trials; and (c) Doctors had not been prescribing Jakafi to their more intermediate (less severe) patients as defendants had led the market to believe was occurring during the Class Period -14- \\x0cCase 1:13-cv-00365-UNA Document 1 Filed 03/06/13 Page 15 of 22 PageID #: 15  based as physicians purportedly having become more \"aware\" of Jakafi and more \"comfortable\" prescribing it',\n",
       " ' The trial is also expected to be completed in the fourth quarter of this year, with potential drug approval in the US in 2012',\n",
       " ' There is a strong precedent with drugs which receive a CRL response in the first instance and then go on to obtain approval',\n",
       " ' These commercial advantages derive from the fact that combination drugs are based on known materials already approved for use by the FDA',\n",
       " ' This alone means that the drug is unlikely to get approved, in my view',\n",
       " ' This feedback is particularly encouraging because it recognizes that our Phase IIB study data 6  \\x0cCase 1:14-cv-10201-MBB Document 1 Filed 01/27/14 Page 7 of 34  set is sufficient for the FDA to consider a filing and allows us to initiate the first step of the registration process for approval of a new drug',\n",
       " \" This lack of disclosure made it impossible for21 the public to gain a meaningful understanding of the drug's potential for FDA approval 8\\t7\",\n",
       " ' This, in turn, made it imperative for defendants to convincethe investment community that the FDA would permit defendants to at least describe Acurox asproviding a deterrent effect in its product label, even if they could not list it as an approvedindication, so the market would believe Acurox was commercially viable By misrepresenting Acurox\\xe2\\x80\\x99s potential for obtaining FDA approval and theCompany\\xe2\\x80\\x99s other drug products during the Class Period, Acura obtained a lucrative third-partylicense agreement that allowed it to obtain tens of millions of dollars worth of milestonepayments; obtained a listing on the Nasdaq Stock Exchange; and obtained a coveted listing onthe Russell 3000 Index',\n",
       " \" To date, none of the Company's drug products, including OCA, have received approval from the U\",\n",
       " \" Unbeknownst to investors however, Incyte' s reported 4Q 2011 and 1Q2012 sales had -2- \\x0cCase 1:13-cv-00365-UNA Document 1 Filed 03/06/13 Page 3 of 22 PageID #: 3   been artificially inflated due to a large number of extremely sick, advanced-stage myelofibrosis patients being prescribed the drug initially upon FDA approval in November 2011, during 4Q 211 and 1Q2012 - patients who had been too sick to participate in the clinical trials - including patients with life expectancies of six months or less\",\n",
       " ' Until such re-inspection is completed and the warning letter is closed out, COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS (cid:9)- 10 - (cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)(cid:9)\\x0cCase3:13-cv-01037-EMC Document1 Filed03/07/13 Page12 of 24  approval of the Company\\xe2\\x80\\x99s pending drug applications listing the Hayward manufacturing facility as a manufacturing location may be withheld by the FDA',\n",
       " ' Vivus continuously hyped Qnexa\\xe2\\x80\\x99s \\xe2\\x80\\x9cremarkable27 safety,\\xe2\\x80\\x9d and its potential for success via NDA approval, while materially understating the health28COMPLAINT FOR VIOLATIONS OF FEDERAL SECURITIES \\tLAWS DOCS\\\\529622v7_ 1 _ Case No \\t\\t\\t\\t\\x0cCase4:10-cv-04957-PJH Document1 Filed11/02/10 Page3 of 371 risks associated with the drug',\n",
       " ' We believe that,  with the exception of eravacycline, most of the antibiotics that are in development or have recently been approved by the FDA that are intended to cover a broad spectrum of bacteria, including Gram-negative bacteria, or solely to address Gram-negative bacteria, are being developed or are approved for use in combination with one or more other antibiotics, and require the addition of a third drug such as metronidazole to address the presence of anaerobic bacteria ',\n",
       " ' We intend to utilize our sublingual spray drug delivery technology and dronabinol formulation capabilities to develop novel formulations of approved medications where we believe 1 2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS (cid:9)- 5 - (cid:9)\\x0cCase 2:13-cv-02563-HRH Document 1 Filed 12/16/13 Page 7 of 21  improved efficacy, onset of action or patient convenience are needed',\n",
       " ' We now market six FDA approved anti-cancer drugs in the United States and the revenue from these drugs helps us to invest in the development and potential expansion of our portfolio targeting larger markets',\n",
       " ' What made FDA approval seem plausible is that the agency has just recently, as a result of a new law, gained the ability to use the \\xe2\\x80\\x9caccelerated approval,\\xe2\\x80\\x9d which means the FDA can approval a drug conditionally, and then automatically yank it if it turns out the medicine doesn\\xe2\\x80\\x99t work in larger studies',\n",
       " \" While I understand the Food and Drug Administration (FDA) is working to ensure that drugs marketed and sold in the United States are safe and effective, I am concerned that KV Pharmaceutical is taking advantage of FDA's approval of Makena and orphan drug determination to achieve rights as the sole source for this limited use of progesterone, leading to a monopolization of treatments to address preterm labors\",\n",
       " ' analyst Stephen Willey is also quoted in the article as stating that Celator is \\xe2\\x80\\x9ca very good strategic fit\\xe2\\x80\\x9d with two approved drugs in its hematology and oncology portfolio',\n",
       " ' and win approval, Laura Jacobus says they may seek an alternative strategy to get 3,4-Dap approved, perhaps in a disease related to LEMS, perhaps with a modified version of the drug',\n",
       " ' for pacritinib, an   investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R  for the treatment of patients with myelofibrosis, in the fourth quarter of 2015 and to   request accelerated approval for the treatment of patients with intermediate and high-risk myelofibrosis with low platelet counts of less than 50,000 per microliter (<50,000/uL) for whom there are no approved drugs',\n",
       " ' orphan drug targeting LEMS, a disease of the central nervous system for which there is not currently an effective treatment approved in the United States',\n",
       " ' \\xe2\\x80\\x9cTIVO-1 is novel in that this Phase 3 clinical study used an approved targeted comparator drug to evaluate first-line RCC treatment,\\xe2\\x80\\x9d said Dr',\n",
       " ' \\xe2\\x80\\x9cWe obtained FDA approval for Triferic, scaled-up manufacturing and launched our novel iron replacement drug in September',\n",
       " '\" Again attempting to dispel any indication that newly prescribed patients were dropping off the drug or reducing prescriptions, defendant Andrews refused to provide any then-current dropout trends, instead encouraging investors to continue relying upon the dated, pre-approval discontinuance data, stating: [I]t\\'s way too early to have a sense of discontinuation rate or compliance in the real world, but we do look to our clinical trial data to inform what we believe is likely to happen',\n",
       " '\" For this reason, the FDA last year decided that the LIGHT study should continue, but that Orexigen would have to launch a new study to satisfy the conditions of the approval of its Contrave drug',\n",
       " '\" Instead, Hemispherx spun the outcome of June FDA meeting as much more positive, even suggesting to investors that FDA was more willing to review and possibly approve Ampligen due to new federal regulations -- the so-called FDASTA legislation -- aimed at accelerating the approval of drug for serious diseases without treatment options',\n",
       " ',  were in  the  development  of  Vyvanse,  a  prodrug  of amphetamine  indicated  for  ADHD,  through  FDA  approval',\n",
       " '5 There are currently no approved drugs that modify the course of this disease, nor any therapies to slow the rate of clinical decline',\n",
       " 'corn  entitled \"The Obsolescence of Provectus\\' Skin Cancer Drug Means Current Speculative Run Ends Badly,\" which stated in part: A speculative mania has overtaken the Pink Sheet stock Provectus Biopharmaceuticals PVCT, triggered by Internet message board and Twitter rumors that FDA officials may sanction an accelerated approval filing of the company\\'s long-delayed skin cancer drug PV-10',\n",
       " '\\xe2\\x80\\x9d  The  August  2016  Press  Release  also  stated  that  \\xe2\\x80\\x9c[b]ased  on  the committees\\xe2\\x80\\x99 votes, Egalet anticipates, if approved, the label for ARYMO ER will describe the product\\xe2\\x80\\x99s abuse-deterrent properties that are expected to reduce, but not totally prevent, abuse of the drug when the tablets are manipulated\\xe2\\x80\\x9d (emphasis added)',\n",
       " '\\xe2\\x80\\x9d  This completed NDA submission is based on a full non-clinical, clinical and manufacturing program for MoxDuo IR, and is being filed under 505(b)(2) regulations wherein approval for a new drug may be expedited by citing historical published evidence supporting each of MoxDuo\\xe2\\x80\\x99s already approved components to supplement the data derived from the robust QRxPharma development program',\n",
       " '\\xe2\\x80\\x9d A complete response letter is issued by the FDA\\xe2\\x80\\x99s Center for Drug Evaluation and Research when the review cycle for a drug is complete and the application is not yet ready for approval'}"
      ]
     },
     "execution_count": 114,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "search_Hc(\"drug approv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "Unigrams_Hc = nltk.ngrams(ls2.split(),1)\n",
    "Bigram_Hc = nltk.ngrams(ls2.split(),2)\n",
    "Trigram_Hc = nltk.ngrams(ls2.split(),3)\n",
    "Fourgram_Hc = nltk.ngrams(ls2.split(),4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[((u'feder', u'secur', u'law'), 1645),\n",
       " ((u'section', u'exchang', u'act'), 1597),\n",
       " ((u'violat', u'feder', u'secur'), 1126),\n",
       " ((u'artifici', u'inflat', u'price'), 986),\n",
       " ((u'violat', u'section', u'exchang'), 713),\n",
       " ((u'control', u'financi', u'report'), 666),\n",
       " ((u'per', u'dilut', u'share'), 664),\n",
       " ((u'intern', u'control', u'financi'), 661),\n",
       " ((u'chief', u'execut', u'offic'), 658),\n",
       " ((u'purchas', u'otherwis', u'acquir'), 647),\n",
       " ((u'secur', u'artifici', u'inflat'), 617),\n",
       " ((u'million', u'per', u'dilut'), 599),\n",
       " ((u'omit', u'fact', u'necessari'), 565),\n",
       " ((u'10b', u'promulg', u'thereund'), 545),\n",
       " ((u'rule', u'10b', u'promulg'), 530),\n",
       " ((u'question', u'law', u'fact'), 528),\n",
       " ((u'exchang', u'act', u'rule'), 523),\n",
       " ((u'light', u'circumst', u'made'), 503),\n",
       " ((u'fulli', u'set', u'forth'), 502),\n",
       " ((u'made', u'fals', u'mislead'), 482),\n",
       " ((u'circumst', u'made', u'mislead'), 473),\n",
       " ((u'net', u'loss', u'million'), 461),\n",
       " ((u'rule', u'civil', u'procedur'), 452),\n",
       " ((u'feder', u'rule', u'civil'), 451),\n",
       " ((u'fact', u'omit', u'fact'), 438),\n",
       " ((u'knew', u'recklessli', u'disregard'), 438),\n",
       " ((u'dilut', u'share', u'revenu'), 426),\n",
       " ((u'untru', u'fact', u'omit'), 425),\n",
       " ((u'financi', u'oper', u'result'), 425),\n",
       " ((u'act', u'rule', u'10b'), 414),\n",
       " ((u'oper', u'fraud', u'deceit'), 413),\n",
       " ((u'phase', u'clinic', u'trial'), 405),\n",
       " ((u'other', u'similarli', u'situat'), 400),\n",
       " ((u'secur', u'exchang', u'act'), 393),\n",
       " ((u'made', u'light', u'circumst'), 390),\n",
       " ((u'make', u'made', u'light'), 389),\n",
       " ((u'loss', u'million', u'per'), 378),\n",
       " ((u'necessari', u'order', u'make'), 375),\n",
       " ((u'exchang', u'act', u'1934'), 373),\n",
       " ((u'fact', u'necessari', u'order'), 372),\n",
       " ((u'bought', u'bought', u'bought'), 369),\n",
       " ((u'realleg', u'everi', u'contain'), 368),\n",
       " ((u'report', u'form', u'sec'), 363),\n",
       " ((u'chang', u'intern', u'control'), 362),\n",
       " ((u'repeat', u'realleg', u'everi'), 360),\n",
       " ((u'year', u'end', u'decemb'), 356),\n",
       " ((u'order', u'make', u'made'), 353),\n",
       " ((u'food', u'drug', u'administr'), 352),\n",
       " ((u'fact', u'necessari', u'make'), 339),\n",
       " ((u'non', u'public', u'inform'), 339),\n",
       " ((u'close', u'per', u'share'), 336),\n",
       " ((u'mislead', u'fail', u'disclos'), 332),\n",
       " ((u'demand', u'trial', u'juri'), 332),\n",
       " ((u'cours', u'busi', u'oper'), 332),\n",
       " ((u'busi', u'oper', u'fraud'), 330),\n",
       " ((u'pursuant', u'section', u'exchang'), 329),\n",
       " ((u'fals', u'mislead', u'fail'), 324),\n",
       " ((u'form', u'sec', u'announc'), 306),\n",
       " ((u'secur', u'exchang', u'commiss'), 305),\n",
       " ((u'disclos', u'chang', u'intern'), 304),\n",
       " ((u'financi', u'inform', u'contain'), 300),\n",
       " ((u'unit', u'district', u'court'), 299),\n",
       " ((u'accur', u'disclos', u'chang'), 296),\n",
       " ((u'fraud', u'deceit', u'upon'), 293),\n",
       " ((u'devic', u'scheme', u'artific'), 292),\n",
       " ((u'employ', u'devic', u'scheme'), 292),\n",
       " ((u'exchang', u'act', u'78aa'), 289),\n",
       " ((u'scheme', u'artific', u'defraud'), 289),\n",
       " ((u'fail', u'disclos', u'fact'), 289),\n",
       " ((u'direct', u'proxim', u'result'), 288),\n",
       " ((u'drug', u'administr', u'fda'), 288),\n",
       " ((u'upon', u'integr', u'market'), 288),\n",
       " ((u'issu', u'fals', u'mislead'), 288),\n",
       " ((u'law', u'fact', u'common'), 286),\n",
       " ((u'practic', u'cours', u'busi'), 285),\n",
       " ((u'reckless', u'disregard', u'truth'), 283),\n",
       " ((u'recklessli', u'disregard', u'fact'), 281),\n",
       " ((u'purchas', u'purchas', u'purchas'), 281),\n",
       " ((u'result', u'wrong', u'conduct'), 278),\n",
       " ((u'instrument', u'interst', u'commerc'), 275),\n",
       " ((u'rule', u'feder', u'rule'), 274),\n",
       " ((u'contain', u'sign', u'certif'), 273),\n",
       " ((u'exchang', u'act', u'78j'), 271),\n",
       " ((u'common', u'stock', u'period'), 270),\n",
       " ((u'compar', u'net', u'loss'), 268),\n",
       " ((u'mean', u'instrument', u'interst'), 268),\n",
       " ((u'use', u'mean', u'instrument'), 267),\n",
       " ((u'jurisdict', u'and', u'venu'), 266),\n",
       " ((u'adequ', u'protect', u'interest'), 265),\n",
       " ((u'contain', u'fulli', u'set'), 264),\n",
       " ((u'exchang', u'commiss', u'sec'), 264),\n",
       " ((u'conduct', u'suffer', u'damag'), 262),\n",
       " ((u'wrong', u'conduct', u'suffer'), 262),\n",
       " ((u'numer', u'joinder', u'impractic'), 259),\n",
       " ((u'everi', u'contain', u'fulli'), 256),\n",
       " ((u'indirectli', u'use', u'mean'), 254),\n",
       " ((u'directli', u'indirectli', u'use'), 253),\n",
       " ((u'thi', u'court', u'jurisdict'), 253),\n",
       " ((u'suffer', u'damag', u'connect'), 251),\n",
       " ((u'net', u'incom', u'million'), 249),\n",
       " ((u'relief', u'court', u'may'), 249),\n",
       " ((u'court', u'may', u'deem'), 247),\n",
       " ((u'superior', u'avail', u'method'), 246),\n",
       " ((u'act', u'control', u'person'), 244),\n",
       " ((u'share', u'common', u'stock'), 243),\n",
       " ((u'effici', u'adjud', u'controversi'), 243),\n",
       " ((u'sign', u'certif', u'pursuant'), 243),\n",
       " ((u'chief', u'financi', u'offic'), 243),\n",
       " ((u'may', u'deem', u'proper'), 242),\n",
       " ((u'report', u'net', u'loss'), 242),\n",
       " ((u'method', u'fair', u'effici'), 242),\n",
       " ((u'fair', u'effici', u'adjud'), 241),\n",
       " ((u'quarterli', u'report', u'form'), 241),\n",
       " ((u'avail', u'method', u'fair'), 240),\n",
       " ((u'busi', u'oper', u'prospect'), 240),\n",
       " ((u'dissemin', u'fals', u'mislead'), 240),\n",
       " ((u'oper', u'result', u'quarter'), 238),\n",
       " ((u'fail', u'disclos', u'advers'), 231),\n",
       " ((u'promulg', u'thereund', u'sec'), 230),\n",
       " ((u'1934', u'exchang', u'act'), 230),\n",
       " ((u'act', u'1934', u'exchang'), 230),\n",
       " ((u'act', u'practic', u'cours'), 230),\n",
       " ((u'within', u'mean', u'section'), 230),\n",
       " ((u'result', u'quarter', u'end'), 230),\n",
       " ((u'engag', u'act', u'practic'), 229),\n",
       " ((u'proxim', u'result', u'wrong'), 227),\n",
       " ((u'issuanc', u'caus', u'correct'), 226),\n",
       " ((u'juri', u'trial', u'demand'), 226),\n",
       " ((u'period', u'prior', u'year'), 226),\n",
       " ((u'prevent', u'issuanc', u'caus'), 225),\n",
       " ((u'claim', u'assert', u'aris'), 224),\n",
       " ((u'all', u'other', u'similarli'), 223),\n",
       " ((u'civil', u'procedur', u'behalf'), 223),\n",
       " ((u'presid', u'chief', u'execut'), 222),\n",
       " ((u'quarter', u'end', u'march'), 221),\n",
       " ((u'announc', u'financi', u'oper'), 221),\n",
       " ((u'inflat', u'price', u'period'), 219),\n",
       " ((u'stock', u'artifici', u'inflat'), 219),\n",
       " ((u'certif', u'pursuant', u'sox'), 218),\n",
       " ((u'princip', u'execut', u'offic'), 217),\n",
       " ((u'serv', u'repres', u'parti'), 217),\n",
       " ((u'fairli', u'adequ', u'protect'), 216),\n",
       " ((u'million', u'compar', u'net'), 215),\n",
       " ((u'protect', u'interest', u'retain'), 213),\n",
       " ((u'fals', u'mislead', u'made'), 211),\n",
       " ((u'claim', u'typic', u'claim'), 211),\n",
       " ((u'price', u'per', u'share'), 210),\n",
       " ((u'interest', u'retain', u'counsel'), 209),\n",
       " ((u'experienc', u'secur', u'litig'), 208),\n",
       " ((u'pursuant', u'exchang', u'act'), 207),\n",
       " ((u'new', u'drug', u'applic'), 207),\n",
       " ((u'behalf', u'all', u'other'), 207),\n",
       " ((u'mean', u'section', u'exchang'), 207),\n",
       " ((u'sec', u'announc', u'financi'), 206),\n",
       " ((u'presumpt', u'relianc', u'establish'), 205),\n",
       " ((u'upon', u'person', u'knowledg'), 204),\n",
       " ((u'fact', u'busi', u'oper'), 204),\n",
       " ((u'omit', u'misrepres', u'fact'), 204),\n",
       " ((u'liabl', u'pursuant', u'section'), 203),\n",
       " ((u'prayer', u'relief', u'wherefor'), 203),\n",
       " ((u'repres', u'heir', u'successor'), 202),\n",
       " ((u'fraud', u'market', u'doctrin'), 201),\n",
       " ((u'heir', u'successor', u'assign'), 201),\n",
       " ((u'share', u'revenu', u'million'), 200),\n",
       " ((u'legal', u'repres', u'heir'), 199),\n",
       " ((u'lhg', u'document', u'pageid'), 198),\n",
       " ((u'misrepresent', u'fail', u'disclos'), 198),\n",
       " ((u'mislead', u'prior', u'shortli'), 198),\n",
       " ((u'necessari', u'make', u'made'), 198),\n",
       " ((u'successor', u'assign', u'entiti'), 197),\n",
       " ((u'accur', u'truth', u'inform'), 196),\n",
       " ((u'exchang', u'act', u'against'), 195),\n",
       " ((u'common', u'stock', u'artifici'), 194),\n",
       " ((u'secur', u'law', u'violat'), 193),\n",
       " ((u'invest', u'public', u'period'), 193),\n",
       " ((u'immedi', u'famili', u'legal'), 192),\n",
       " ((u'million', u'per', u'share'), 191),\n",
       " ((u'while', u'exact', u'number'), 190),\n",
       " ((u'famili', u'legal', u'repres'), 190),\n",
       " ((u'truth', u'inform', u'respect'), 189),\n",
       " ((u'entiti', u'control', u'interest'), 189),\n",
       " ((u'number', u'unknown', u'time'), 188),\n",
       " ((u'exact', u'number', u'unknown'), 188),\n",
       " ((u'count', u'violat', u'section'), 188),\n",
       " ((u'quarter', u'end', u'june'), 187),\n",
       " ((u'repres', u'parti', u'behalf'), 187),\n",
       " ((u'activ', u'trade', u'nasdaq'), 187),\n",
       " ((u'common', u'stock', u'trade'), 187),\n",
       " ((u'section', u'1934', u'act'), 186),\n",
       " ((u'act', u'against', u'individu'), 186),\n",
       " ((u'disclosur', u'control', u'procedur'), 185),\n",
       " ((u'act', u'78j', u'78t'), 185),\n",
       " ((u'section', u'secur', u'act'), 185),\n",
       " ((u'court', u'jurisdict', u'subject'), 185),\n",
       " ((u'deceiv', u'invest', u'public'), 184),\n",
       " ((u'common', u'question', u'law'), 184),\n",
       " ((u'assign', u'entiti', u'control'), 184),\n",
       " ((u'and', u'venu', u'claim'), 183),\n",
       " ((u'dea', u'document', u'pageid'), 183),\n",
       " ((u'unit', u'secur', u'exchang'), 182),\n",
       " ((u'78j', u'78t', u'rule'), 182),\n",
       " ((u'individu', u'behalf', u'all'), 182),\n",
       " ((u'jurisdict', u'subject', u'matter'), 182),\n",
       " ((u'entitl', u'presumpt', u'relianc'), 181),\n",
       " ((u'condit', u'result', u'oper'), 180),\n",
       " ((u'telephon', u'commun', u'facil'), 180),\n",
       " ((u'financi', u'condit', u'result'), 180),\n",
       " ((u'venu', u'claim', u'assert'), 180),\n",
       " ((u'interst', u'telephon', u'commun'), 180),\n",
       " ((u'unknown', u'time', u'ascertain'), 179),\n",
       " ((u'made', u'untru', u'fact'), 179),\n",
       " ((u'mail', u'interst', u'telephon'), 179),\n",
       " ((u'facil', u'nation', u'secur'), 179),\n",
       " ((u'ascertain', u'appropri', u'discoveri'), 178),\n",
       " ((u'trial', u'juri', u'date'), 178),\n",
       " ((u'law', u'fact', u'exist'), 178),\n",
       " ((u'fals', u'mislead', u'omiss'), 178),\n",
       " ((u'execut', u'offic', u'ceo'), 177),\n",
       " ((u'proper', u'measur', u'damag'), 177),\n",
       " ((u'fee', u'expert', u'fee'), 177),\n",
       " ((u'act', u'reckless', u'disregard'), 177),\n",
       " ((u'sole', u'affect', u'individu'), 176),\n",
       " ((u'question', u'sole', u'affect'), 176),\n",
       " ((u'predomin', u'question', u'sole'), 176),\n",
       " ((u'affect', u'individu', u'among'), 175),\n",
       " ((u'interst', u'commerc', u'includ'), 175),\n",
       " ((u'exist', u'predomin', u'question'), 175),\n",
       " ((u'breach', u'fiduciari', u'duti'), 175),\n",
       " ((u'fact', u'exist', u'predomin'), 175),\n",
       " ((u'sustain', u'damag', u'proper'), 173),\n",
       " ((u'appropri', u'discoveri', u'believ'), 173),\n",
       " ((u'damag', u'proper', u'measur'), 172),\n",
       " ((u'commun', u'facil', u'nation'), 172),\n",
       " ((u'among', u'question', u'law'), 172),\n",
       " ((u'individu', u'among', u'question'), 172),\n",
       " ((u'individu', u'litig', u'make'), 171),\n",
       " ((u'use', u'form', u'notic'), 171),\n",
       " ((u'damag', u'suffer', u'individu'), 171),\n",
       " ((u'violat', u'feder', u'law'), 171),\n",
       " ((u'time', u'ascertain', u'appropri'), 171),\n",
       " ((u'clw', u'document', u'pageid'), 171),\n",
       " ((u'invest', u'public', u'includ'), 171),\n",
       " ((u'fals', u'mislead', u'inform'), 170),\n",
       " ((u'may', u'rel', u'small'), 170),\n",
       " ((u'pendenc', u'mail', u'use'), 170),\n",
       " ((u'identifi', u'record', u'maintain'), 170),\n",
       " ((u'customarili', u'use', u'secur'), 170),\n",
       " ((u'document', u'usdc', u'colorado'), 170),\n",
       " ((u'wrong', u'done', u'there'), 169),\n",
       " ((u'individu', u'may', u'rel'), 169),\n",
       " ((u'there', u'difficulti', u'manag'), 169),\n",
       " ((u'rel', u'small', u'expens'), 169),\n",
       " ((u'counsel', u'compet', u'experienc'), 169),\n",
       " ((u'suffer', u'individu', u'may'), 169),\n",
       " ((u'adjud', u'controversi', u'sinc'), 169),\n",
       " ((u'retain', u'counsel', u'compet'), 169),\n",
       " ((u'mail', u'use', u'form'), 169),\n",
       " ((u'individu', u'liabl', u'pursuant'), 168),\n",
       " ((u'burden', u'individu', u'litig'), 168),\n",
       " ((u'done', u'there', u'difficulti'), 168),\n",
       " ((u'may', u'identifi', u'record'), 168),\n",
       " ((u'director', u'relev', u'time'), 167),\n",
       " ((u'sinc', u'joinder', u'impractic'), 167),\n",
       " ((u'per', u'share', u'close'), 167),\n",
       " ((u'transfer', u'agent', u'may'), 167),\n",
       " ((u'controversi', u'sinc', u'joinder'), 167),\n",
       " ((u'compet', u'experienc', u'secur'), 166),\n",
       " ((u'individu', u'duti', u'dissemin'), 166),\n",
       " ((u'small', u'expens', u'burden'), 166),\n",
       " ((u'herebi', u'demand', u'trial'), 166),\n",
       " ((u'fact', u'common', u'whether'), 166),\n",
       " ((u'claim', u'similarli', u'affect'), 166),\n",
       " ((u'litig', u'make', u'imposs'), 165),\n",
       " ((u'reason', u'cost', u'expens'), 165),\n",
       " ((u'statutori', u'safe', u'harbor'), 165),\n",
       " ((u'agent', u'may', u'notifi'), 165),\n",
       " ((u'notifi', u'pendenc', u'mail'), 165),\n",
       " ((u'typic', u'claim', u'similarli'), 165),\n",
       " ((u'furthermor', u'damag', u'suffer'), 164),\n",
       " ((u'2015', u'2015', u'2015'), 164),\n",
       " ((u'would', u'purchas', u'otherwis'), 164),\n",
       " ((u'may', u'notifi', u'pendenc'), 164),\n",
       " ((u'joinder', u'impractic', u'furthermor'), 164),\n",
       " ((u'fact', u'set', u'forth'), 163),\n",
       " ((u'expens', u'burden', u'individu'), 163),\n",
       " ((u'control', u'interest', u'numer'), 163),\n",
       " ((u'disregard', u'truth', u'fail'), 163),\n",
       " ((u'relev', u'time', u'immedi'), 162),\n",
       " ((u'exist', u'set', u'forth'), 162),\n",
       " ((u'set', u'forth', u'reason'), 162),\n",
       " ((u'impractic', u'furthermor', u'damag'), 161),\n",
       " ((u'interest', u'numer', u'joinder'), 161),\n",
       " ((u'conduct', u'violat', u'feder'), 161),\n",
       " ((u'dissemin', u'invest', u'public'), 161),\n",
       " ((u'time', u'immedi', u'famili'), 161),\n",
       " ((u'pursuant', u'feder', u'rule'), 161),\n",
       " ((u'support', u'exist', u'set'), 161),\n",
       " ((u'declin', u'market', u'valu'), 161),\n",
       " ((u'advers', u'non', u'public'), 160),\n",
       " ((u'precipit', u'declin', u'market'), 160)]"
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "counter_tri_Hc = Counter(Trigram_Hc)\n",
    "counter_tri_Hc.most_common(300)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[((u'free', u'cash', u'flow'), 301),\n",
       " ((u'earn', u'per', u'share'), 233),\n",
       " ((u'fourth', u'quarter', u'fiscal'), 211),\n",
       " ((u'announc', u'financi', u'result'), 200),\n",
       " ((u'proxi', u'fail', u'disclos'), 200),\n",
       " ((u'fiscal', u'year', u'end'), 197),\n",
       " ((u'first', u'quarter', u'fiscal'), 189),\n",
       " ((u'pertin', u'part', u'follow'), 188),\n",
       " ((u'compar', u'net', u'incom'), 187),\n",
       " ((u'set', u'forth', u'individu'), 182),\n",
       " ((u'rule', u'14a', u'promulg'), 176),\n",
       " ((u'second', u'quarter', u'fiscal'), 165),\n",
       " ((u'third', u'quarter', u'fiscal'), 161),\n",
       " ((u'discount', u'cash', u'flow'), 160),\n",
       " ((u'14a', u'promulg', u'thereund'), 155),\n",
       " ((u'unlev', u'free', u'cash'), 153),\n",
       " ((u'share', u'revenu', u'billion'), 153),\n",
       " ((u'violat', u'section', u'1934'), 152),\n",
       " ((u'non', u'gaap', u'oper'), 152),\n",
       " ((u'section', u'secur', u'exchang'), 151),\n",
       " ((u'issu', u'announc', u'financi'), 151),\n",
       " ((u'connect', u'propos', u'transact'), 151),\n",
       " ((u'trade', u'artifici', u'inflat'), 151),\n",
       " ((u'wholli', u'own', u'subsidiari'), 148),\n",
       " ((u'approv', u'propos', u'transact'), 147),\n",
       " ((u'gaap', u'net', u'incom'), 144),\n",
       " ((u'upon', u'inform', u'belief'), 144),\n",
       " ((u'day', u'day', u'oper'), 143),\n",
       " ((u'report', u'net', u'incom'), 143),\n",
       " ((u'incom', u'million', u'per'), 143),\n",
       " ((u'quarter', u'fiscal', u'year'), 142),\n",
       " ((u'purchas', u'common', u'stock'), 142),\n",
       " ((u'three', u'month', u'end'), 141),\n",
       " ((u'disclos', u'fact', u'necessari'), 140),\n",
       " ((u'involv', u'day', u'day'), 137),\n",
       " ((u'violat', u'secur', u'exchang'), 135),\n",
       " ((u'proxi', u'fals', u'mislead'), 134),\n",
       " ((u'individu', u'act', u'control'), 134),\n",
       " ((u'non', u'gaap', u'net'), 134),\n",
       " ((u'1934', u'act', u'rule'), 133),\n",
       " ((u'fals', u'mislead', u'proxi'), 132),\n",
       " ((u'violat', u'section', u'secur'), 131),\n",
       " ((u'similar', u'customarili', u'use'), 131),\n",
       " ((u'notic', u'similar', u'customarili'), 131),\n",
       " ((u'form', u'notic', u'similar'), 131),\n",
       " ((u'individu', u'violat', u'section'), 131),\n",
       " ((u'wrong', u'conduct', u'violat'), 130),\n",
       " ((u'cash', u'flow', u'analysi'), 130),\n",
       " ((u'per', u'share', u'cash'), 128),\n",
       " ((u'control', u'directli', u'indirectli'), 128),\n",
       " ((u'control', u'influenc', u'control'), 128),\n",
       " ((u'deceit', u'upon', u'purchas'), 127),\n",
       " ((u'influenc', u'control', u'influenc'), 126),\n",
       " ((u'influenc', u'control', u'directli'), 126),\n",
       " ((u'similarli', u'affect', u'wrong'), 126),\n",
       " ((u'venu', u'proper', u'district'), 125),\n",
       " ((u'affect', u'wrong', u'conduct'), 125),\n",
       " ((u'oper', u'incom', u'million'), 124),\n",
       " ((u'includ', u'content', u'dissemin'), 124),\n",
       " ((u'violat', u'exchang', u'act'), 123)]"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "U = [c[0] for c in counter_tri_Hc.most_common(300)]\n",
    "[t for t in counter_tri_tech.most_common(300) if not t[0] in U ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 2",
   "language": "python",
   "name": "python2"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
